data_2n6v_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2n6v _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.404 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.404 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 . . . . . 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.425 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.425 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 . . . . . 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 . . . . . 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 . . . . . 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.402 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.402 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.438 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.438 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.426 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 . . . . . 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.45 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.45 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 . . . . . 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.462 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 . . . . . 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' MET . . . . . 0.433 ' HE2' ' CD2' ' A' ' 16' ' ' TRP . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . 0.433 ' CD2' ' HE2' ' A' ' 5' ' ' MET . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 . . . . . 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.407 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . 0.407 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 . . . . . 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' THR . . . . . 0.436 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' PRO . . . . . 0.436 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -137.24 41.7 2.42 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -75.85 -176.96 3.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 114.935 1.458 . . . . 0.0 114.935 171.791 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.27 76.27 32.59 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 114.166 1.173 . . . . 0.0 114.166 -163.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -81.25 73.51 5.91 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.515 2.81 . . . . 0.0 110.452 -175.872 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -58.04 167.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.644 1.977 . . . . 0.0 115.975 174.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -150.16 151.6 33.35 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 126.755 2.022 . . . . 0.0 114.178 165.47 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 . . . . . 0 C--O 1.25 1.124 0 N-CA-C 116.556 2.058 . . . . 0.0 116.556 177.722 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -124.08 23.94 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -72.69 165.46 24.73 Favored 'General case' 0 N--CA 1.449 -0.499 0 O-C-N 124.806 1.316 . . . . 0.0 114.244 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 74.58 164.63 0.14 Allowed Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.502 2.721 . . . . 0.0 111.961 -166.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -78.97 55.48 5.61 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 124.745 3.63 . . . . 0.0 112.492 170.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -60.3 154.8 19.22 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 113.692 -1.594 . . . . 0.0 114.685 -175.071 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.66 159.57 30.51 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.822 2.449 . . . . 0.0 112.581 162.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.5 t70 . . . . . 0 C--O 1.25 1.116 0 CA-C-O 117.337 -1.316 . . . . 0.0 112.279 -179.045 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.404 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.404 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -127.13 23.52 6.48 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -62.34 141.35 58.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.279 1.031 . . . . 0.0 111.918 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 31.16 65.12 0.98 Allowed Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 126.85 2.594 . . . . 0.0 114.263 -173.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -73.26 172.99 14.46 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 122.595 2.197 . . . . 0.0 113.975 -162.361 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.18 169.92 16.96 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.975 3.31 . . . . 0.0 113.684 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.52 38.02 3.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 126.489 1.915 . . . . 0.0 112.403 -170.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 34.0 t70 . . . . . 0 C--O 1.25 1.097 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 177.423 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -133.86 141.59 47.46 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . 0.265 57.5 m80 51.56 43.49 29.69 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 130.244 3.417 . . . . 0.0 117.726 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.32 156.02 77.72 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-O 116.708 -1.615 . . . . 0.0 113.658 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_exo -53.24 113.73 1.42 Allowed 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.368 2.046 . . . . 0.0 112.364 -176.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 6.7 mp 53.99 31.15 12.97 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 124.194 1.95 . . . . 0.0 112.172 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.12 -179.97 6.55 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 129.315 3.046 . . . . 0.0 112.689 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 C--O 1.25 1.091 0 C-N-CA 125.932 1.693 . . . . 0.0 112.368 174.721 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.425 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.425 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -128.56 4.97 5.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . 0.563 ' CG ' ' H ' ' A' ' 20' ' ' ALA . 5.2 t-80 51.91 -172.9 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 126.481 1.912 . . . . 0.0 114.394 -161.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.563 ' H ' ' CG ' ' A' ' 19' ' ' HIS . . . -62.96 131.43 94.65 Favored Pre-proline 0 N--CA 1.448 -0.55 0 C-N-CA 126.419 1.888 . . . . 0.0 109.611 -163.612 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -69.93 172.07 13.49 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 124.629 3.553 . . . . 0.0 112.112 -178.641 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -154.04 169.57 23.19 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 126.295 2.247 . . . . 0.0 110.991 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 40.86 65.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 127.636 2.374 . . . . 0.0 114.071 -177.567 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 125.64 1.576 . . . . 0.0 112.715 177.609 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -140.23 111.25 6.99 Favored 'General case' 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -120.0 164.63 15.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.037 0.935 . . . . 0.0 112.05 -171.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.98 80.72 11.1 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 125.14 1.376 . . . . 0.0 110.236 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.59 59.13 7.12 Favored 'Trans proline' 0 N--CA 1.449 -1.099 1 C-N-CA 125.944 4.43 . . . . 0.0 110.811 -171.38 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 96.5 mt -73.7 122.42 22.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 128.324 2.649 . . . . 0.0 113.536 178.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 49.93 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.988 3.315 . . . . 0.0 118.849 -167.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 . . . . . 0 C--O 1.25 1.079 0 C-N-CA 128.95 2.9 . . . . 0.0 110.354 -169.549 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.441 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.441 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -131.47 117.63 19.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 14.7 t60 59.12 165.74 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 131.382 3.873 . . . . 0.0 113.405 -178.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.63 73.21 35.44 Favored Pre-proline 0 N--CA 1.449 -0.522 0 O-C-N 117.561 -3.212 . . . . 0.0 110.446 -171.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -79.87 177.55 8.23 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.005 1.803 . . . . 0.0 110.577 177.08 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 4.6 pp -62.28 152.93 32.27 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.286 159.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.48 101.63 1.36 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.151 0.58 . . . . 0.0 111.061 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.1 t70 . . . . . 0 C--O 1.249 1.044 0 C-N-CA 128.509 2.723 . . . . 0.0 107.877 161.795 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -117.37 13.57 14.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 46.7 m80 56.95 163.85 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 127.783 2.433 . . . . 0.0 114.857 -162.125 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -59.51 144.21 84.81 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-O 117.902 -1.047 . . . . 0.0 112.192 176.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.13 159.32 37.32 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 CA-C-N 119.809 0.967 . . . . 0.0 112.202 -171.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.2 pp -54.62 167.01 0.39 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 114.717 1.376 . . . . 0.0 114.717 164.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.87 20.15 5.99 Favored 'General case' 0 N--CA 1.45 -0.428 0 O-C-N 118.405 -2.684 . . . . 0.0 115.525 -166.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 C--O 1.249 1.051 0 O-C-N 118.533 -2.604 . . . . 0.0 115.432 171.087 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.402 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.402 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 2.0 pt20 -140.49 110.83 6.67 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.28 176.63 9.6 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 127.016 2.126 . . . . 0.0 111.724 170.089 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.74 153.66 65.02 Favored Pre-proline 0 N--CA 1.449 -0.49 0 C-N-CA 129.584 3.154 . . . . 0.0 110.735 174.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -77.37 161.15 31.96 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.576 3.518 . . . . 0.0 113.303 169.309 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 72.9 mt -81.16 24.33 0.53 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 113.08 -1.873 . . . . 0.0 113.395 -159.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.07 -8.67 24.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 124.578 3.354 . . . . 0.0 119.246 -157.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 . . . . . 0 C--O 1.249 1.079 0 CA-C-N 122.035 2.198 . . . . 0.0 115.178 -177.241 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.438 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.438 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -137.51 28.11 2.75 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -75.68 163.01 27.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 116.869 2.174 . . . . 0.0 116.869 -168.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.3 159.71 68.5 Favored Pre-proline 0 N--CA 1.45 -0.474 0 O-C-N 126.163 2.165 . . . . 0.0 109.774 175.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -80.31 152.39 20.79 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.177 3.252 . . . . 0.0 113.719 -168.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.4 mt -92.68 106.61 18.56 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 121.365 1.893 . . . . 0.0 114.14 -177.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.84 -11.49 2.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.514 2.725 . . . . 0.0 117.332 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 . . . . . 0 C--O 1.25 1.089 0 C-N-CA 129.142 2.977 . . . . 0.0 113.993 -175.099 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -135.76 73.05 1.45 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -79.19 19.8 0.55 Allowed 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 128.482 2.713 . . . . 0.0 114.179 -169.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.52 158.69 53.49 Favored Pre-proline 0 N--CA 1.448 -0.525 0 C-N-CA 128.081 2.552 . . . . 0.0 110.345 -177.508 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.88 164.66 34.97 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 124.274 3.316 . . . . 0.0 112.374 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -140.73 168.71 19.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 125.345 1.458 . . . . 0.0 111.7 -179.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.7 91.99 2.02 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.268 1.027 . . . . 0.0 111.053 168.471 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.25 1.128 0 C-N-CA 126.782 2.033 . . . . 0.0 112.735 161.535 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.426 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.426 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -82.53 -35.05 27.62 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 12.5 m-70 -68.63 130.17 42.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 129.25 3.02 . . . . 0.0 113.494 -155.553 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -54.21 122.36 36.16 Favored Pre-proline 0 N--CA 1.449 -0.506 0 C-N-CA 125.506 1.523 . . . . 0.0 114.421 -178.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.85 92.89 1.02 Allowed 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 123.881 3.054 . . . . 0.0 111.47 -173.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 2.5 pt? -61.48 148.91 40.37 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.933 1.293 . . . . 0.0 113.787 175.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.67 25.95 4.37 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 125.904 1.681 . . . . 0.0 114.113 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.5 t70 . . . . . 0 C--O 1.25 1.098 0 C-N-CA 127.115 2.166 . . . . 0.0 113.904 -174.879 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.435 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -77.14 -11.59 59.83 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 21.4 t-80 -68.78 171.63 7.57 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.815 1.646 . . . . 0.0 112.019 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -111.3 83.33 3.97 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 166.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.05 130.15 29.78 Favored 'Trans proline' 0 N--CA 1.448 -1.177 0 C-N-CA 123.573 2.849 . . . . 0.0 110.94 -168.115 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . 0.283 38.1 mt 61.23 -75.66 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.885 2.474 . . . . 0.0 111.878 -161.048 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -166.25 164.05 17.72 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 126.819 2.048 . . . . 0.0 111.893 164.35 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 . . . . . 0 C--O 1.249 1.075 0 C-N-CA 128.583 2.753 . . . . 0.0 112.662 167.525 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.43 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.43 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -81.99 -12.37 58.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -69.73 168.35 15.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.305 -0.872 . . . . 0.0 112.211 171.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -128.02 93.24 39.83 Favored Pre-proline 0 N--CA 1.45 -0.472 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.529 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -70.39 142.77 45.99 Favored 'Trans proline' 0 N--CA 1.448 -1.153 0 C-N-CA 122.47 2.113 . . . . 0.0 110.971 172.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.59 176.4 5.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.194 1.924 . . . . 0.0 116.194 -177.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 50.28 35.71 11.2 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.163 2.985 . . . . 0.0 113.074 173.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 . . . . . 0 C--O 1.249 1.037 0 CA-C-N 120.445 1.475 . . . . 0.0 113.163 167.536 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.45 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.45 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -161.35 156.71 24.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -65.02 172.52 2.88 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 122.759 1.266 . . . . 0.0 108.876 156.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -47.54 143.66 5.43 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 117.134 2.272 . . . . 0.0 117.134 -166.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -68.0 131.88 24.96 Favored 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 124.917 3.745 . . . . 0.0 114.593 -171.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 27.0 mt -72.79 68.37 0.86 Allowed 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 129.479 3.112 . . . . 0.0 107.242 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.94 -11.7 60.18 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 114.682 1.364 . . . . 0.0 114.682 -154.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 C--O 1.25 1.093 0 C-N-CA 127.922 2.489 . . . . 0.0 109.305 174.91 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.462 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -117.1 79.58 1.36 Allowed 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 64.05 164.25 0.13 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 131.634 3.974 . . . . 0.0 111.781 -159.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -117.56 73.76 8.34 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 160.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -76.78 171.75 17.44 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.536 2.824 . . . . 0.0 115.656 -161.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.8 pt? -103.66 176.29 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.554 2.342 . . . . 0.0 111.116 166.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.32 -23.49 0.67 Allowed 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.55 166.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 4.2 p30 . . . . . 0 C--O 1.251 1.135 0 C-N-CA 128.491 2.716 . . . . 0.0 112.428 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.436 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . 0.436 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 59.91 14.04 4.01 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -55.01 -64.52 0.81 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.531 1.132 . . . . 0.0 113.094 167.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -170.82 149.48 2.85 Favored Pre-proline 0 N--CA 1.448 -0.525 0 CA-C-N 112.073 -2.33 . . . . 0.0 113.469 168.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -85.3 105.59 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.158 1 C-N-CA 127.445 5.43 . . . . 0.0 110.575 160.101 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.5 mt -110.97 -179.55 3.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 O-C-N 124.388 1.055 . . . . 0.0 112.593 -171.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.27 -9.02 0.76 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.094 1.516 . . . . 0.0 115.094 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.25 1.109 0 C-N-CA 131.173 3.789 . . . . 0.0 113.984 162.539 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' MET . . . . . 0.433 ' HE2' ' CD2' ' A' ' 16' ' ' TRP . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . 0.433 ' CD2' ' HE2' ' A' ' 5' ' ' MET . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.595 ' C ' ' H ' ' A' ' 20' ' ' ALA . 5.9 tt0 -135.5 6.32 3.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 56.53 -14.99 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 128.08 2.552 . . . . 0.0 114.764 -163.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.595 ' H ' ' C ' ' A' ' 18' ' ' GLN . . . -63.89 142.16 98.08 Favored Pre-proline 0 N--CA 1.449 -0.488 0 O-C-N 119.895 -1.753 . . . . 0.0 112.024 176.062 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -70.6 172.13 14.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 123.699 2.933 . . . . 0.0 113.055 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 90.4 mt -69.05 176.67 3.05 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.887 -2.383 . . . . 0.0 114.541 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . 0.446 . . 75.1 38.2 0.44 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 115.807 1.781 . . . . 0.0 115.807 -169.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--O 1.25 1.104 0 N-CA-C 118.121 2.638 . . . . 0.0 118.121 177.904 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.407 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . 0.407 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 -152.07 132.72 13.95 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 11.4 m170 59.12 -176.08 0.09 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.917 2.087 . . . . 0.0 113.799 -168.62 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.72 70.07 37.29 Favored Pre-proline 0 N--CA 1.449 -0.499 0 C-N-CA 123.667 0.787 . . . . 0.0 112.399 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -60.9 116.66 3.5 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 124.382 3.388 . . . . 0.0 111.218 176.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.0 pp -69.33 -11.06 60.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.163 1.385 . . . . 0.0 112.103 175.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.9 160.69 2.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 121.196 1.817 . . . . 0.0 114.769 168.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 128.847 2.859 . . . . 0.0 113.651 -168.815 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.436 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' PRO . . . . . 0.436 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.09 1.69 4.26 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 71.54 -175.66 0.18 Allowed 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.368 2.267 . . . . 0.0 111.429 -167.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 52.07 66.16 5.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.915 2.886 . . . . 0.0 114.487 176.608 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.28 173.32 5.31 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 O-C-N 125.134 2.123 . . . . 0.0 112.183 -178.401 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -136.28 -0.64 2.44 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.659 1.984 . . . . 0.0 115.737 -172.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -77.59 40.51 0.3 Allowed 'General case' 0 N--CA 1.449 -0.507 1 C-N-CA 132.597 4.359 . . . . 0.0 113.777 174.325 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 . . . . . 0 C--O 1.251 1.164 0 C-N-CA 130.66 3.584 . . . . 0.0 112.772 175.671 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.53 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.53 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.459 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 . . . . . 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.549 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 . . . . . 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 . . . . . 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.485 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 . . . . . 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.489 ' HD2' ' H ' ' A' ' 18' ' ' GLN . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.494 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.489 ' H ' ' HD2' ' A' ' 2' ' ' PRO . 2.0 pt20 . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.493 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.437 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.437 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.439 HG22 ' CE1' ' A' ' 15' ' ' TYR . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' TYR . . . . . 0.439 ' CE1' HG22 ' A' ' 6' ' ' VAL . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.446 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.419 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.508 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.508 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 . . . . . 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.414 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.568 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.568 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.414 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 . . . . . 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.483 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 . . . . . 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ASP . . . . . 0.479 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 8' ' ' LEU . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 . . . . . 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.537 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLN . . . . . 0.537 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 . . . . . 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' THR . . . . . 0.516 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' PRO . . . . . 0.516 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -137.24 41.7 2.42 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -75.85 -176.96 3.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 114.935 1.458 . . . . 0.0 114.935 171.791 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.27 76.27 32.59 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 114.166 1.173 . . . . 0.0 114.166 -163.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -81.25 73.51 5.91 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.515 2.81 . . . . 0.0 110.452 -175.872 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -58.04 167.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.644 1.977 . . . . 0.0 115.975 174.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -150.16 151.6 33.35 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 126.755 2.022 . . . . 0.0 114.178 165.47 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 . . . . . 0 C--O 1.25 1.124 0 N-CA-C 116.556 2.058 . . . . 0.0 116.556 177.722 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -124.08 23.94 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -72.69 165.46 24.73 Favored 'General case' 0 N--CA 1.449 -0.499 0 O-C-N 124.806 1.316 . . . . 0.0 114.244 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 21' ' ' PRO . . . 74.58 164.63 0.14 Allowed Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.502 2.721 . . . . 0.0 111.961 -166.803 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 20' ' ' ALA . 44.4 Cg_endo -78.97 55.48 5.61 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 124.745 3.63 . . . . 0.0 112.492 170.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -60.3 154.8 19.22 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 113.692 -1.594 . . . . 0.0 114.685 -175.071 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.66 159.57 30.51 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.822 2.449 . . . . 0.0 112.581 162.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.5 t70 . . . . . 0 C--O 1.25 1.116 0 CA-C-O 117.337 -1.316 . . . . 0.0 112.279 -179.045 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.53 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.53 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -127.13 23.52 6.48 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -62.34 141.35 58.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.279 1.031 . . . . 0.0 111.918 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 31.16 65.12 0.98 Allowed Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 126.85 2.594 . . . . 0.0 114.263 -173.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -73.26 172.99 14.46 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 122.595 2.197 . . . . 0.0 113.975 -162.361 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.18 169.92 16.96 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.975 3.31 . . . . 0.0 113.684 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.52 38.02 3.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 126.489 1.915 . . . . 0.0 112.403 -170.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 34.0 t70 . . . . . 0 C--O 1.25 1.097 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 177.423 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.459 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -133.86 141.59 47.46 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . 0.265 57.5 m80 51.56 43.49 29.69 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 130.244 3.417 . . . . 0.0 117.726 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.32 156.02 77.72 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-O 116.708 -1.615 . . . . 0.0 113.658 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_exo -53.24 113.73 1.42 Allowed 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.368 2.046 . . . . 0.0 112.364 -176.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 6.7 mp 53.99 31.15 12.97 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 124.194 1.95 . . . . 0.0 112.172 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.12 -179.97 6.55 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 129.315 3.046 . . . . 0.0 112.689 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 C--O 1.25 1.091 0 C-N-CA 125.932 1.693 . . . . 0.0 112.368 174.721 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.549 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -128.56 4.97 5.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' HIS . . . . . 0.503 ' CG ' ' H ' ' A' ' 20' ' ' ALA . 5.2 t-80 51.91 -172.9 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 126.481 1.912 . . . . 0.0 114.394 -161.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.503 ' H ' ' CG ' ' A' ' 19' ' ' HIS . . . -62.96 131.43 94.65 Favored Pre-proline 0 N--CA 1.448 -0.55 0 C-N-CA 126.419 1.888 . . . . 0.0 109.611 -163.612 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -69.93 172.07 13.49 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 124.629 3.553 . . . . 0.0 112.112 -178.641 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -154.04 169.57 23.19 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 126.295 2.247 . . . . 0.0 110.991 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 40.86 65.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 127.636 2.374 . . . . 0.0 114.071 -177.567 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 125.64 1.576 . . . . 0.0 112.715 177.609 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -140.23 111.25 6.99 Favored 'General case' 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -120.0 164.63 15.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.037 0.935 . . . . 0.0 112.05 -171.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.98 80.72 11.1 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 125.14 1.376 . . . . 0.0 110.236 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.59 59.13 7.12 Favored 'Trans proline' 0 N--CA 1.449 -1.099 1 C-N-CA 125.944 4.43 . . . . 0.0 110.811 -171.38 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 96.5 mt -73.7 122.42 22.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 128.324 2.649 . . . . 0.0 113.536 178.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 49.93 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.988 3.315 . . . . 0.0 118.849 -167.576 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 . . . . . 0 C--O 1.25 1.079 0 C-N-CA 128.95 2.9 . . . . 0.0 110.354 -169.549 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -131.47 117.63 19.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 14.7 t60 59.12 165.74 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 131.382 3.873 . . . . 0.0 113.405 -178.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.63 73.21 35.44 Favored Pre-proline 0 N--CA 1.449 -0.522 0 O-C-N 117.561 -3.212 . . . . 0.0 110.446 -171.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -79.87 177.55 8.23 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.005 1.803 . . . . 0.0 110.577 177.08 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 4.6 pp -62.28 152.93 32.27 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.286 159.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.48 101.63 1.36 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.151 0.58 . . . . 0.0 111.061 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.1 t70 . . . . . 0 C--O 1.249 1.044 0 C-N-CA 128.509 2.723 . . . . 0.0 107.877 161.795 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.485 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -117.37 13.57 14.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 46.7 m80 56.95 163.85 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 127.783 2.433 . . . . 0.0 114.857 -162.125 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -59.51 144.21 84.81 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-O 117.902 -1.047 . . . . 0.0 112.192 176.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.13 159.32 37.32 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 CA-C-N 119.809 0.967 . . . . 0.0 112.202 -171.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.2 pp -54.62 167.01 0.39 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 114.717 1.376 . . . . 0.0 114.717 164.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.87 20.15 5.99 Favored 'General case' 0 N--CA 1.45 -0.428 0 O-C-N 118.405 -2.684 . . . . 0.0 115.525 -166.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 C--O 1.249 1.051 0 O-C-N 118.533 -2.604 . . . . 0.0 115.432 171.087 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.489 ' HD2' ' H ' ' A' ' 18' ' ' GLN . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.494 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.489 ' H ' ' HD2' ' A' ' 2' ' ' PRO . 2.0 pt20 -140.49 110.83 6.67 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.28 176.63 9.6 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 127.016 2.126 . . . . 0.0 111.724 170.089 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.74 153.66 65.02 Favored Pre-proline 0 N--CA 1.449 -0.49 0 C-N-CA 129.584 3.154 . . . . 0.0 110.735 174.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -77.37 161.15 31.96 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.576 3.518 . . . . 0.0 113.303 169.309 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 72.9 mt -81.16 24.33 0.53 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 113.08 -1.873 . . . . 0.0 113.395 -159.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.07 -8.67 24.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 124.578 3.354 . . . . 0.0 119.246 -157.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 . . . . . 0 C--O 1.249 1.079 0 CA-C-N 122.035 2.198 . . . . 0.0 115.178 -177.241 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.493 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -137.51 28.11 2.75 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -75.68 163.01 27.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 116.869 2.174 . . . . 0.0 116.869 -168.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.3 159.71 68.5 Favored Pre-proline 0 N--CA 1.45 -0.474 0 O-C-N 126.163 2.165 . . . . 0.0 109.774 175.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -80.31 152.39 20.79 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.177 3.252 . . . . 0.0 113.719 -168.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.4 mt -92.68 106.61 18.56 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 121.365 1.893 . . . . 0.0 114.14 -177.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.84 -11.49 2.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.514 2.725 . . . . 0.0 117.332 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 . . . . . 0 C--O 1.25 1.089 0 C-N-CA 129.142 2.977 . . . . 0.0 113.993 -175.099 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -135.76 73.05 1.45 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -79.19 19.8 0.55 Allowed 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 128.482 2.713 . . . . 0.0 114.179 -169.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.52 158.69 53.49 Favored Pre-proline 0 N--CA 1.448 -0.525 0 C-N-CA 128.081 2.552 . . . . 0.0 110.345 -177.508 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.88 164.66 34.97 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 124.274 3.316 . . . . 0.0 112.374 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -140.73 168.71 19.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 125.345 1.458 . . . . 0.0 111.7 -179.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.7 91.99 2.02 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.268 1.027 . . . . 0.0 111.053 168.471 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.25 1.128 0 C-N-CA 126.782 2.033 . . . . 0.0 112.735 161.535 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.437 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.437 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.439 HG22 ' CE1' ' A' ' 15' ' ' TYR . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' TYR . . . . . 0.439 ' CE1' HG22 ' A' ' 6' ' ' VAL . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.446 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -82.53 -35.05 27.62 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 12.5 m-70 -68.63 130.17 42.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 129.25 3.02 . . . . 0.0 113.494 -155.553 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -54.21 122.36 36.16 Favored Pre-proline 0 N--CA 1.449 -0.506 0 C-N-CA 125.506 1.523 . . . . 0.0 114.421 -178.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.85 92.89 1.02 Allowed 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 123.881 3.054 . . . . 0.0 111.47 -173.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.462 ' H ' HD23 ' A' ' 22' ' ' LEU . 2.5 pt? -61.48 148.91 40.37 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.933 1.293 . . . . 0.0 113.787 175.477 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.67 25.95 4.37 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 125.904 1.681 . . . . 0.0 114.113 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.5 t70 . . . . . 0 C--O 1.25 1.098 0 C-N-CA 127.115 2.166 . . . . 0.0 113.904 -174.879 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.419 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -77.14 -11.59 59.83 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 21.4 t-80 -68.78 171.63 7.57 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.815 1.646 . . . . 0.0 112.019 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -111.3 83.33 3.97 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 166.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.05 130.15 29.78 Favored 'Trans proline' 0 N--CA 1.448 -1.177 0 C-N-CA 123.573 2.849 . . . . 0.0 110.94 -168.115 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . 0.283 38.1 mt 61.23 -75.66 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.885 2.474 . . . . 0.0 111.878 -161.048 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -166.25 164.05 17.72 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 126.819 2.048 . . . . 0.0 111.893 164.35 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 . . . . . 0 C--O 1.249 1.075 0 C-N-CA 128.583 2.753 . . . . 0.0 112.662 167.525 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.508 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.508 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -81.99 -12.37 58.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -69.73 168.35 15.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.305 -0.872 . . . . 0.0 112.211 171.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -128.02 93.24 39.83 Favored Pre-proline 0 N--CA 1.45 -0.472 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.529 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -70.39 142.77 45.99 Favored 'Trans proline' 0 N--CA 1.448 -1.153 0 C-N-CA 122.47 2.113 . . . . 0.0 110.971 172.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.59 176.4 5.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.194 1.924 . . . . 0.0 116.194 -177.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 50.28 35.71 11.2 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.163 2.985 . . . . 0.0 113.074 173.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 . . . . . 0 C--O 1.249 1.037 0 CA-C-N 120.445 1.475 . . . . 0.0 113.163 167.536 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.414 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.568 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.568 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.414 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -161.35 156.71 24.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -65.02 172.52 2.88 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 122.759 1.266 . . . . 0.0 108.876 156.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -47.54 143.66 5.43 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 117.134 2.272 . . . . 0.0 117.134 -166.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -68.0 131.88 24.96 Favored 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 124.917 3.745 . . . . 0.0 114.593 -171.109 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 27.0 mt -72.79 68.37 0.86 Allowed 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 129.479 3.112 . . . . 0.0 107.242 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.94 -11.7 60.18 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 114.682 1.364 . . . . 0.0 114.682 -154.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 C--O 1.25 1.093 0 C-N-CA 127.922 2.489 . . . . 0.0 109.305 174.91 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.483 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -117.1 79.58 1.36 Allowed 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 64.05 164.25 0.13 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 131.634 3.974 . . . . 0.0 111.781 -159.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -117.56 73.76 8.34 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 160.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -76.78 171.75 17.44 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.536 2.824 . . . . 0.0 115.656 -161.365 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' LEU . . . . . 0.528 ' H ' HD23 ' A' ' 22' ' ' LEU . 1.8 pt? -103.66 176.29 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.554 2.342 . . . . 0.0 111.116 166.725 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.32 -23.49 0.67 Allowed 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.55 166.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 4.2 p30 . . . . . 0 C--O 1.251 1.135 0 C-N-CA 128.491 2.716 . . . . 0.0 112.428 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASP . . . . . 0.479 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 59.91 14.04 4.01 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -55.01 -64.52 0.81 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.531 1.132 . . . . 0.0 113.094 167.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -170.82 149.48 2.85 Favored Pre-proline 0 N--CA 1.448 -0.525 0 CA-C-N 112.073 -2.33 . . . . 0.0 113.469 168.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -85.3 105.59 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.158 1 C-N-CA 127.445 5.43 . . . . 0.0 110.575 160.101 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.5 mt -110.97 -179.55 3.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 O-C-N 124.388 1.055 . . . . 0.0 112.593 -171.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.27 -9.02 0.76 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.094 1.516 . . . . 0.0 115.094 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.25 1.109 0 C-N-CA 131.173 3.789 . . . . 0.0 113.984 162.539 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 8' ' ' LEU . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' ALA . 5.9 tt0 -135.5 6.32 3.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 56.53 -14.99 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 128.08 2.552 . . . . 0.0 114.764 -163.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLN . . . -63.89 142.16 98.08 Favored Pre-proline 0 N--CA 1.449 -0.488 0 O-C-N 119.895 -1.753 . . . . 0.0 112.024 176.062 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -70.6 172.13 14.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 123.699 2.933 . . . . 0.0 113.055 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 90.4 mt -69.05 176.67 3.05 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.887 -2.383 . . . . 0.0 114.541 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . 0.446 . . 75.1 38.2 0.44 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 115.807 1.781 . . . . 0.0 115.807 -169.077 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--O 1.25 1.104 0 N-CA-C 118.121 2.638 . . . . 0.0 118.121 177.904 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.537 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLN . . . . . 0.537 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 -152.07 132.72 13.95 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 11.4 m170 59.12 -176.08 0.09 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.917 2.087 . . . . 0.0 113.799 -168.62 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.72 70.07 37.29 Favored Pre-proline 0 N--CA 1.449 -0.499 0 C-N-CA 123.667 0.787 . . . . 0.0 112.399 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -60.9 116.66 3.5 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 124.382 3.388 . . . . 0.0 111.218 176.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.0 pp -69.33 -11.06 60.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.163 1.385 . . . . 0.0 112.103 175.113 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.9 160.69 2.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 121.196 1.817 . . . . 0.0 114.769 168.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 128.847 2.859 . . . . 0.0 113.651 -168.815 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.516 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' PRO . . . . . 0.516 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.09 1.69 4.26 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 71.54 -175.66 0.18 Allowed 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.368 2.267 . . . . 0.0 111.429 -167.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 52.07 66.16 5.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.915 2.886 . . . . 0.0 114.487 176.608 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.28 173.32 5.31 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 O-C-N 125.134 2.123 . . . . 0.0 112.183 -178.401 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -136.28 -0.64 2.44 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.659 1.984 . . . . 0.0 115.737 -172.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -77.59 40.51 0.3 Allowed 'General case' 0 N--CA 1.449 -0.507 1 C-N-CA 132.597 4.359 . . . . 0.0 113.777 174.325 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 . . . . . 0 C--O 1.251 1.164 0 C-N-CA 130.66 3.584 . . . . 0.0 112.772 175.671 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 . . . . . 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 . . . . . 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.53 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.53 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 . . . . . 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.459 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 . . . . . 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.549 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 . . . . . 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 . . . . . 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 . . . . . 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.485 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 . . . . . 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.489 ' HD2' ' H ' ' A' ' 18' ' ' GLN . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.494 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.489 ' H ' ' HD2' ' A' ' 2' ' ' PRO . 2.0 pt20 . . . . . 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.493 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 . . . . . 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.437 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.437 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.439 HG22 ' CE1' ' A' ' 15' ' ' TYR . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . 0.439 ' CE1' HG22 ' A' ' 6' ' ' VAL . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.446 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? . . . . . 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.419 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.508 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.508 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 . . . . . 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.414 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.568 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.568 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.414 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 . . . . . 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.483 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 . . . . . 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . 0.479 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 . . . . . 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 8' ' ' LEU . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 5.9 tt0 . . . . . 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.537 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . 0.537 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 . . . . . 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . 0.516 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' PRO . . . . . 0.516 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 . . . . . 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.482 0 N-CA-C 119.192 2.437 . . . . 0.0 119.192 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_endo -93.34 0.43 3.46 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 123.129 2.553 . . . . 0.0 116.041 -164.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 12.8 p -61.66 174.01 0.72 Allowed Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 126.007 1.723 . . . . 0.0 112.691 174.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_endo -95.61 2.9 2.3 Favored 'Trans proline' 0 N--CA 1.449 -1.11 0 CA-C-N 122.888 2.067 . . . . 0.0 113.806 174.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 76.1 mtm -83.59 106.45 15.32 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.759 1.623 . . . . 0.0 109.997 -173.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 p -71.04 119.64 17.66 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 CA-C-O 124.421 2.058 . . . . 0.0 115.529 -177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 160.33 -173.5 36.93 Favored Glycine 0 CA--C 1.522 0.492 0 CA-C-N 112.995 -1.911 . . . . 0.0 109.775 -171.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -63.07 145.77 54.71 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.866 1.266 . . . . 0.0 114.345 -166.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.0 t70 -122.78 121.62 36.75 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 127.065 2.146 . . . . 0.0 110.486 -179.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 t -58.16 -18.84 28.45 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 174.102 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . 0.27 88.4 t -112.69 -71.89 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 O-C-N 119.331 -2.106 . . . . 0.0 112.333 175.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 19.4 m -178.95 153.51 0.64 Allowed 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 123.129 0.572 . . . . 0.0 109.517 -174.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 116.2 168.23 15.08 Favored Glycine 0 CA--C 1.522 0.522 0 CA-C-O 123.954 1.863 . . . . 0.0 113.293 -176.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 43.8 mt-30 -86.95 -8.19 57.46 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 117.72 -3.224 . . . . 0.0 113.826 -173.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 74.4 m-85 -120.76 171.22 8.76 Favored 'General case' 0 N--CA 1.449 -0.52 0 C-N-CA 127.378 2.271 . . . . 0.0 107.728 -175.343 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.7 m95 -62.82 154.46 29.8 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 126.744 2.018 . . . . 0.0 112.744 175.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -83.04 165.9 19.22 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-O 124.458 2.075 . . . . 0.0 114.21 164.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -137.24 41.7 2.42 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 127.934 2.494 . . . . 0.0 112.895 -179.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 48.6 m-70 -75.85 -176.96 3.59 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 114.935 1.458 . . . . 0.0 114.935 171.791 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -121.27 76.27 32.59 Favored Pre-proline 0 N--CA 1.449 -0.491 0 N-CA-C 114.166 1.173 . . . . 0.0 114.166 -163.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 97.7 Cg_endo -81.25 73.51 5.91 Favored 'Trans proline' 0 N--CA 1.45 -1.084 0 C-N-CA 123.515 2.81 . . . . 0.0 110.452 -175.872 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -58.04 167.09 1.33 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 126.644 1.977 . . . . 0.0 115.975 174.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -150.16 151.6 33.35 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 126.755 2.022 . . . . 0.0 114.178 165.47 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 . . . . . 0 C--O 1.25 1.124 0 N-CA-C 116.556 2.058 . . . . 0.0 116.556 177.722 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.439 0 CA-C-O 116.902 -2.054 . . . . 0.0 115.69 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 0.5 OUTLIER -95.59 -6.65 1.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.112 1 C-N-CA 125.711 4.274 . . . . 0.0 112.884 -170.001 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 17.8 p -63.32 165.17 11.8 Favored Pre-proline 0 N--CA 1.449 -0.49 0 N-CA-C 114.501 1.297 . . . . 0.0 114.501 -176.281 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_endo -85.98 3.38 7.04 Favored 'Trans proline' 0 N--CA 1.45 -1.079 0 C-N-CA 123.299 2.666 . . . . 0.0 111.774 173.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 71.3 mtp -83.49 94.06 7.94 Favored 'General case' 0 N--CA 1.449 -0.519 1 O-C-N 116.245 -4.034 . . . . 0.0 109.601 -175.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.2 t -64.62 115.37 2.98 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 119.651 -1.906 . . . . 0.0 109.105 -173.433 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -172.87 -121.81 0.63 Allowed Glycine 0 CA--C 1.522 0.498 0 C-N-CA 126.903 2.192 . . . . 0.0 113.272 -174.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pp -136.58 154.28 50.73 Favored 'General case' 0 N--CA 1.449 -0.504 0 CA-C-O 123.255 1.502 . . . . 0.0 112.926 176.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -104.58 179.06 4.38 Favored 'General case' 0 N--CA 1.449 -0.487 0 C-N-CA 126.86 2.064 . . . . 0.0 111.66 -169.559 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -70.44 -27.32 64.16 Favored 'General case' 0 N--CA 1.448 -0.548 0 C-N-CA 125.627 1.571 . . . . 0.0 112.645 169.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 66.5 t -134.98 -61.92 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.488 0 C-N-CA 125.809 1.644 . . . . 0.0 113.165 -172.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 15.9 t -156.88 165.88 34.93 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 125.447 1.499 . . . . 0.0 110.507 -171.124 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 89.8 178.91 44.83 Favored Glycine 0 C--N 1.336 0.545 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.869 -174.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -111.73 5.7 19.34 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 125.747 1.619 . . . . 0.0 114.892 -162.647 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -123.56 162.73 22.38 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 126.64 1.976 . . . . 0.0 112.466 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.3 m95 -63.04 165.22 7.24 Favored 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 116.319 1.97 . . . . 0.0 116.319 168.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 32.8 t0 -127.9 154.38 45.59 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 124.859 1.264 . . . . 0.0 109.576 -173.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 17.7 pt20 -124.08 23.94 8.34 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 117.816 2.525 . . . . 0.0 117.816 -159.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 22.1 p-80 -72.69 165.46 24.73 Favored 'General case' 0 N--CA 1.449 -0.499 0 O-C-N 124.806 1.316 . . . . 0.0 114.244 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.751 ' HB1' ' HD2' ' A' ' 21' ' ' PRO . . . 74.58 164.63 0.14 Allowed Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.502 2.721 . . . . 0.0 111.961 -166.803 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.751 ' HD2' ' HB1' ' A' ' 20' ' ' ALA . 44.4 Cg_endo -78.97 55.48 5.61 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 C-N-CA 124.745 3.63 . . . . 0.0 112.492 170.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -60.3 154.8 19.22 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 113.692 -1.594 . . . . 0.0 114.685 -175.071 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.66 159.57 30.51 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 127.822 2.449 . . . . 0.0 112.581 162.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.5 t70 . . . . . 0 C--O 1.25 1.116 0 CA-C-O 117.337 -1.316 . . . . 0.0 112.279 -179.045 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.554 0 N-CA-C 116.761 1.465 . . . . 0.0 116.761 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -85.68 88.9 0.8 Allowed 'Trans proline' 0 N--CA 1.449 -1.107 0 C-N-CA 124.298 3.332 . . . . 0.0 112.762 177.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.53 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 72.3 p -137.99 173.94 4.82 Favored Pre-proline 0 N--CA 1.451 -0.412 0 O-C-N 120.426 -1.421 . . . . 0.0 112.663 164.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.53 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 66.2 Cg_endo -86.02 -7.86 8.05 Favored 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 123.724 2.949 . . . . 0.0 113.928 171.045 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 65.4 mtm -76.03 101.3 5.22 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.18 0.992 . . . . 0.0 110.781 179.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 34.2 m -60.63 149.24 7.84 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 CA-C-O 122.22 1.01 . . . . 0.0 110.206 177.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 158.79 -149.52 19.67 Favored Glycine 0 C--N 1.335 0.525 0 CA-C-O 116.382 -2.343 . . . . 0.0 110.467 -178.883 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.5 mt -103.81 172.42 6.81 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.836 1.654 . . . . 0.0 113.266 160.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -122.77 167.58 13.32 Favored 'General case' 0 N--CA 1.449 -0.495 0 C-N-CA 126.581 1.952 . . . . 0.0 110.948 -176.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 4.9 p -61.65 -31.82 71.95 Favored 'General case' 0 N--CA 1.449 -0.518 0 N-CA-C 115.523 1.675 . . . . 0.0 115.523 165.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -115.94 -70.86 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.506 0 C-N-CA 127.563 2.345 . . . . 0.0 108.77 -179.19 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 78.5 p -161.43 163.42 30.5 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 -168.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 100.37 175.69 30.06 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 125.611 1.577 . . . . 0.0 116.362 173.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 66.4 mt-30 -71.37 -7.48 47.44 Favored 'General case' 0 N--CA 1.448 -0.565 0 C-N-CA 128.985 2.914 . . . . 0.0 115.241 -173.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -141.07 164.47 30.18 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.786 2.435 . . . . 0.0 114.072 -166.189 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 10.9 m0 -61.72 164.63 5.95 Favored 'General case' 0 N--CA 1.449 -0.506 0 O-C-N 119.685 -1.885 . . . . 0.0 112.943 172.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -93.8 176.85 6.2 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.953 1.701 . . . . 0.0 113.039 164.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -127.13 23.52 6.48 Favored 'General case' 0 N--CA 1.451 -0.415 0 C-N-CA 125.405 1.482 . . . . 0.0 110.779 165.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -62.34 141.35 58.35 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 124.279 1.031 . . . . 0.0 111.918 174.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 31.16 65.12 0.98 Allowed Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 126.85 2.594 . . . . 0.0 114.263 -173.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -73.26 172.99 14.46 Favored 'Trans proline' 0 N--CA 1.449 -1.118 0 C-N-CA 122.595 2.197 . . . . 0.0 113.975 -162.361 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -144.18 169.92 16.96 Favored 'General case' 0 N--CA 1.449 -0.493 0 C-N-CA 129.975 3.31 . . . . 0.0 113.684 -179.29 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.52 38.02 3.46 Favored 'General case' 0 N--CA 1.45 -0.474 0 C-N-CA 126.489 1.915 . . . . 0.0 112.403 -170.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 34.0 t70 . . . . . 0 C--O 1.25 1.097 0 N-CA-C 116.021 1.86 . . . . 0.0 116.021 177.423 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.459 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.499 0 N-CA-C 121.524 3.37 . . . . 0.0 121.524 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -84.22 -2.48 10.07 Favored 'Trans proline' 0 N--CA 1.449 -1.094 0 C-N-CA 122.23 1.953 . . . . 0.0 115.387 -176.167 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 13.7 p -74.79 169.59 19.3 Favored Pre-proline 0 N--CA 1.45 -0.442 0 O-C-N 118.969 -2.332 . . . . 0.0 112.734 -172.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 65.0 Cg_endo -88.38 -1.48 6.83 Favored 'Trans proline' 0 N--CA 1.449 -1.13 0 C-N-CA 123.725 2.95 . . . . 0.0 116.197 165.935 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 69.0 mmm -76.97 108.37 9.98 Favored 'General case' 0 N--CA 1.449 -0.481 0 O-C-N 119.136 -2.227 . . . . 0.0 112.936 177.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 19.1 m -63.39 142.38 16.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 O-C-N 117.903 -2.998 . . . . 0.0 108.076 -170.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.85 -135.87 3.38 Favored Glycine 0 C--N 1.335 0.497 0 O-C-N 120.263 -1.523 . . . . 0.0 112.63 -177.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.6 mt -126.46 152.82 45.92 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 130.162 3.385 . . . . 0.0 108.848 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -145.31 147.79 32.73 Favored 'General case' 0 N--CA 1.448 -0.537 0 O-C-N 118.663 -2.523 . . . . 0.0 109.844 -174.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 78.2 p -76.98 -15.12 59.74 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 113.408 -1.724 . . . . 0.0 115.29 177.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.9 t -136.52 -58.86 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.515 0 C-N-CA 125.914 1.686 . . . . 0.0 109.338 -167.157 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 8.4 t -90.61 -169.0 2.24 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 127.143 2.177 . . . . 0.0 114.942 -175.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -69.69 -165.01 4.55 Favored Glycine 0 C--N 1.334 0.472 0 C-N-CA 126.996 2.236 . . . . 0.0 114.635 173.096 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 -79.54 58.68 2.76 Favored 'General case' 0 N--CA 1.449 -0.514 0 C-N-CA 127.843 2.457 . . . . 0.0 113.068 -161.374 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -143.35 156.97 44.83 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 125.343 1.457 . . . . 0.0 110.999 172.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.6 m95 -58.92 149.48 26.97 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 126.734 2.014 . . . . 0.0 111.833 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.459 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 1.9 p30 -107.14 88.42 2.73 Favored 'General case' 0 N--CA 1.448 -0.53 0 C-N-CA 128.458 2.703 . . . . 0.0 108.274 177.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 3.2 pt20 -133.86 141.59 47.46 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-O 120.908 0.385 . . . . 0.0 111.112 163.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . 0.265 57.5 m80 51.56 43.49 29.69 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 130.244 3.417 . . . . 0.0 117.726 176.543 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -64.32 156.02 77.72 Favored Pre-proline 0 N--CA 1.449 -0.502 0 CA-C-O 116.708 -1.615 . . . . 0.0 113.658 -176.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_exo -53.24 113.73 1.42 Allowed 'Trans proline' 0 N--CA 1.448 -1.173 0 C-N-CA 122.368 2.046 . . . . 0.0 112.364 -176.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 6.7 mp 53.99 31.15 12.97 Favored 'General case' 0 N--CA 1.449 -0.517 0 CA-C-O 124.194 1.95 . . . . 0.0 112.172 179.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.12 -179.97 6.55 Favored 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 129.315 3.046 . . . . 0.0 112.689 178.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 . . . . . 0 C--O 1.25 1.091 0 C-N-CA 125.932 1.693 . . . . 0.0 112.368 174.721 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 118.857 2.303 . . . . 0.0 118.857 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -97.36 4.7 1.53 Allowed 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 124.492 3.462 . . . . 0.0 114.514 -167.403 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.549 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 17.2 p -71.68 163.56 65.39 Favored Pre-proline 0 N--CA 1.449 -0.485 0 N-CA-C 117.635 2.457 . . . . 0.0 117.635 178.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 93.6 Cg_endo -75.3 8.21 2.63 Favored 'Trans proline' 0 N--CA 1.448 -1.157 1 C-N-CA 126.092 4.528 . . . . 0.0 114.363 171.878 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -92.35 100.73 13.25 Favored 'General case' 0 N--CA 1.449 -0.511 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 -178.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.329 1.8 p -64.76 129.28 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-O 116.96 -1.495 . . . . 0.0 114.319 -179.526 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.73 -168.37 32.24 Favored Glycine 0 CA--C 1.522 0.514 0 CA-C-O 116.55 -2.25 . . . . 0.0 116.668 -169.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 59.8 mt -70.24 133.7 47.3 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-N 121.806 2.803 . . . . 0.0 114.227 179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -80.0 173.98 12.05 Favored 'General case' 0 N--CA 1.449 -0.503 0 CA-C-N 120.148 1.34 . . . . 0.0 112.725 173.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.2 m -81.62 -19.71 41.25 Favored 'General case' 0 N--CA 1.449 -0.492 0 O-C-N 117.356 -3.34 . . . . 0.0 113.821 170.407 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.3 t -141.22 -64.6 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.472 0 C-N-CA 127.261 2.224 . . . . 0.0 111.086 172.342 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 69.8 m -145.79 156.57 43.67 Favored 'General case' 0 N--CA 1.449 -0.51 0 CA-C-N 119.594 1.088 . . . . 0.0 113.758 -166.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 90.79 175.3 44.25 Favored Glycine 0 CA--C 1.522 0.497 0 CA-C-O 118.657 -1.08 . . . . 0.0 111.933 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -111.92 19.12 18.21 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 116.146 1.906 . . . . 0.0 116.146 -162.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 26.6 m-85 -132.09 168.08 18.6 Favored 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 129.843 3.257 . . . . 0.0 115.77 166.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.2 m95 -58.81 156.36 11.38 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 130.114 3.366 . . . . 0.0 114.834 175.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 16.5 t70 -102.09 170.05 8.35 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 127.876 2.47 . . . . 0.0 113.815 175.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 4.0 tt0 -128.56 4.97 5.6 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 121.294 -0.879 . . . . 0.0 112.624 174.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . 0.503 ' CG ' ' H ' ' A' ' 20' ' ' ALA . 5.2 t-80 51.91 -172.9 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 126.481 1.912 . . . . 0.0 114.394 -161.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.503 ' H ' ' CG ' ' A' ' 19' ' ' HIS . . . -62.96 131.43 94.65 Favored Pre-proline 0 N--CA 1.448 -0.55 0 C-N-CA 126.419 1.888 . . . . 0.0 109.611 -163.612 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -69.93 172.07 13.49 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 124.629 3.553 . . . . 0.0 112.112 -178.641 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -154.04 169.57 23.19 Favored 'General case' 0 N--CA 1.449 -0.512 0 O-C-N 126.295 2.247 . . . . 0.0 110.991 178.127 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 40.86 65.77 0.74 Allowed 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 127.636 2.374 . . . . 0.0 114.071 -177.567 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 9.8 p-10 . . . . . 0 C--O 1.25 1.125 0 C-N-CA 125.64 1.576 . . . . 0.0 112.715 177.609 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.502 0 CA-C-O 118.791 -1.005 . . . . 0.0 111.513 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_exo -84.22 -7.26 10.08 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 N-CA-C 122.069 3.834 . . . . 0.0 122.069 -173.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.48 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 28.7 p -63.97 171.6 2.39 Favored Pre-proline 0 N--CA 1.448 -0.537 0 N-CA-C 117.037 2.236 . . . . 0.0 117.037 -179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.48 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 83.8 Cg_endo -87.77 8.88 4.02 Favored 'Trans proline' 0 N--CA 1.45 -1.073 1 C-N-CA 126.347 4.698 . . . . 0.0 113.964 161.256 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 85.8 mmm -89.86 122.91 33.35 Favored 'General case' 0 N--CA 1.449 -0.478 0 CA-C-N 120.854 1.661 . . . . 0.0 107.549 172.086 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.5 p -77.04 128.65 37.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.503 0 O-C-N 119.542 -1.974 . . . . 0.0 113.03 -178.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 172.6 -153.01 17.87 Favored Glycine 0 C--N 1.335 0.508 0 O-C-N 120.886 -1.134 . . . . 0.0 112.443 -173.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 16.8 mt -100.55 144.65 29.28 Favored 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 131.166 3.787 . . . . 0.0 112.951 176.017 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -98.07 -163.96 1.09 Allowed 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 123.804 0.841 . . . . 0.0 112.161 177.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 47.4 m -117.62 -16.82 10.07 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 116.619 2.081 . . . . 0.0 116.619 171.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 92.3 t -129.4 -54.2 1.21 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 123.382 2.81 . . . . 0.0 109.918 171.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 67.7 p -158.75 177.79 10.8 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 125.876 1.67 . . . . 0.0 113.672 -172.048 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 88.52 -172.28 40.86 Favored Glycine 0 C--N 1.335 0.496 0 CA-C-O 116.525 -2.264 . . . . 0.0 112.253 -169.13 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.9 pt20 -123.49 -17.18 6.57 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 117.499 2.407 . . . . 0.0 117.499 -167.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . 0.277 2.5 m-85 -109.48 -165.94 1.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 130.016 3.326 . . . . 0.0 113.366 -173.929 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.7 m0 -59.96 151.81 25.23 Favored 'General case' 0 N--CA 1.45 -0.467 0 O-C-N 119.198 -2.189 . . . . 0.0 111.675 160.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -87.16 170.34 11.58 Favored 'General case' 0 N--CA 1.449 -0.519 0 O-C-N 119.756 -1.84 . . . . 0.0 113.225 171.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -140.23 111.25 6.99 Favored 'General case' 0 N--CA 1.448 -0.539 0 O-C-N 117.588 -3.195 . . . . 0.0 111.225 -179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 35.9 m80 -120.0 164.63 15.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.037 0.935 . . . . 0.0 112.05 -171.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.98 80.72 11.1 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 125.14 1.376 . . . . 0.0 110.236 -179.426 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -81.59 59.13 7.12 Favored 'Trans proline' 0 N--CA 1.449 -1.099 1 C-N-CA 125.944 4.43 . . . . 0.0 110.811 -171.38 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 96.5 mt -73.7 122.42 22.32 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 128.324 2.649 . . . . 0.0 113.536 178.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 49.93 168.13 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 129.988 3.315 . . . . 0.0 118.849 -167.576 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 25.7 m-20 . . . . . 0 C--O 1.25 1.079 0 C-N-CA 128.95 2.9 . . . . 0.0 110.354 -169.549 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.579 0 N-CA-C 114.822 0.689 . . . . 0.0 114.822 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -84.76 6.15 5.89 Favored 'Trans proline' 0 N--CA 1.45 -1.075 1 C-N-CA 125.959 4.439 . . . . 0.0 115.981 -168.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 43.0 p -76.58 165.41 52.89 Favored Pre-proline 0 N--CA 1.448 -0.533 0 O-C-N 120.143 -1.598 . . . . 0.0 109.187 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -85.01 -2.05 9.51 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 123.962 3.108 . . . . 0.0 112.975 169.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 2.0 mpt? -73.34 94.99 2.11 Favored 'General case' 0 N--CA 1.45 -0.447 0 O-C-N 119.655 -1.903 . . . . 0.0 112.662 179.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 32.0 m -57.53 137.44 19.65 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.493 0 O-C-N 121.1 -1.0 . . . . 0.0 112.896 178.865 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 139.54 16.8 0.52 Allowed Glycine 0 C--N 1.335 0.523 0 N-CA-C 118.47 2.148 . . . . 0.0 118.47 -176.004 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . 0.288 7.5 mp 77.94 150.45 0.11 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.593 2.357 . . . . 0.0 113.373 169.065 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -81.42 -172.88 4.05 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.659 1.984 . . . . 0.0 113.414 -167.353 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.0 p -58.0 -39.84 79.26 Favored 'General case' 0 N--CA 1.45 -0.46 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 166.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 47.2 t -132.5 -51.53 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.511 0 CA-C-O 116.926 -1.511 . . . . 0.0 109.467 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 70.1 m -142.43 130.73 22.21 Favored 'General case' 0 N--CA 1.449 -0.475 0 O-C-N 124.99 1.431 . . . . 0.0 114.59 -170.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 136.99 158.2 7.89 Favored Glycine 0 C--N 1.335 0.485 0 C-N-CA 126.597 2.046 . . . . 0.0 111.047 -177.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 13.4 pt20 -80.11 -17.6 52.14 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 116.618 2.081 . . . . 0.0 116.618 179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 55.0 m-85 -117.36 158.02 25.15 Favored 'General case' 0 N--CA 1.449 -0.502 0 O-C-N 120.442 -1.411 . . . . 0.0 110.726 -179.517 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 31.3 m0 -60.07 165.05 3.57 Favored 'General case' 0 N--CA 1.449 -0.512 0 C-N-CA 127.388 2.275 . . . . 0.0 110.715 178.131 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 33.0 t0 -89.73 169.9 10.89 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.811 1.644 . . . . 0.0 109.732 161.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 19.7 pt20 -131.47 117.63 19.08 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.863 -3.023 . . . . 0.0 110.279 170.152 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 14.7 t60 59.12 165.74 0.05 Allowed 'General case' 0 N--CA 1.45 -0.452 0 C-N-CA 131.382 3.873 . . . . 0.0 113.405 -178.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.63 73.21 35.44 Favored Pre-proline 0 N--CA 1.449 -0.522 0 O-C-N 117.561 -3.212 . . . . 0.0 110.446 -171.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 78.6 Cg_endo -79.87 177.55 8.23 Favored 'Trans proline' 0 N--CA 1.449 -1.112 0 C-N-CA 122.005 1.803 . . . . 0.0 110.577 177.08 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 4.6 pp -62.28 152.93 32.27 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.286 159.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.48 101.63 1.36 Allowed 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.151 0.58 . . . . 0.0 111.061 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 14.1 t70 . . . . . 0 C--O 1.249 1.044 0 C-N-CA 128.509 2.723 . . . . 0.0 107.877 161.795 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.448 -0.501 0 CA-C-O 115.262 -2.966 . . . . 0.0 115.049 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_endo -96.5 4.53 1.84 Allowed 'Trans proline' 0 N--CA 1.45 -1.07 0 CA-C-N 122.4 3.1 . . . . 0.0 115.961 -175.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.485 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 32.5 p -60.66 167.16 3.57 Favored Pre-proline 0 N--CA 1.449 -0.503 0 O-C-N 119.77 -1.831 . . . . 0.0 111.318 -173.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 26.3 Cg_endo -86.51 7.91 4.7 Favored 'Trans proline' 0 N--CA 1.449 -1.099 0 C-N-CA 122.194 1.93 . . . . 0.0 114.653 170.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 89.9 mtp -85.47 97.3 9.95 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 123.947 0.899 . . . . 0.0 112.204 171.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 7.6 p -72.72 121.02 22.4 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 -175.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 157.65 -157.25 28.01 Favored Glycine 0 C--N 1.336 0.549 0 C-N-CA 126.248 1.88 . . . . 0.0 110.844 -174.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.3 tp -75.21 122.09 23.12 Favored 'General case' 0 N--CA 1.449 -0.525 0 N-CA-C 115.727 1.751 . . . . 0.0 115.727 -171.146 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -84.89 145.08 27.98 Favored 'General case' 0 N--CA 1.449 -0.504 0 C-N-CA 125.251 1.42 . . . . 0.0 112.917 167.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 8.4 m -61.51 -23.25 65.79 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 117.979 -2.951 . . . . 0.0 115.157 167.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 87.7 t -115.84 -81.29 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 128.43 2.692 . . . . 0.0 108.867 -175.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.8 m -150.45 160.56 43.67 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-N 119.344 0.975 . . . . 0.0 112.963 -164.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 113.49 -151.06 18.44 Favored Glycine 0 CA--C 1.522 0.494 0 CA-C-O 121.815 0.675 . . . . 0.0 114.693 172.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.9 pt20 -131.18 -1.45 4.03 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 125.002 1.321 . . . . 0.0 112.713 177.327 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 89.9 m-85 -121.74 168.67 11.55 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 130.649 3.58 . . . . 0.0 112.167 173.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.6 m0 -68.93 162.28 26.98 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 128.405 2.682 . . . . 0.0 112.51 -179.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -98.75 168.3 10.23 Favored 'General case' 0 N--CA 1.449 -0.48 0 CA-C-O 124.515 2.102 . . . . 0.0 111.98 158.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.5 tt0 -117.37 13.57 14.54 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.629 1.972 . . . . 0.0 114.695 -168.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 46.7 m80 56.95 163.85 0.02 OUTLIER 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 127.783 2.433 . . . . 0.0 114.857 -162.125 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -59.51 144.21 84.81 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-O 117.902 -1.047 . . . . 0.0 112.192 176.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 92.8 Cg_endo -76.13 159.32 37.32 Favored 'Trans proline' 0 N--CA 1.449 -1.126 0 CA-C-N 119.809 0.967 . . . . 0.0 112.202 -171.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.2 pp -54.62 167.01 0.39 Allowed 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 114.717 1.376 . . . . 0.0 114.717 164.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -128.87 20.15 5.99 Favored 'General case' 0 N--CA 1.45 -0.428 0 O-C-N 118.405 -2.684 . . . . 0.0 115.525 -166.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 13.8 m-20 . . . . . 0 C--O 1.249 1.051 0 O-C-N 118.533 -2.604 . . . . 0.0 115.432 171.087 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.526 0 N-CA-C 108.925 -1.67 . . . . 0.0 108.925 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.489 ' HD2' ' H ' ' A' ' 18' ' ' GLN . 25.9 Cg_exo -76.09 -4.95 15.78 Favored 'Trans proline' 0 N--CA 1.45 -1.048 0 CA-C-N 122.418 3.109 . . . . 0.0 116.949 -170.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.494 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 20.1 p -77.99 169.3 21.55 Favored Pre-proline 0 N--CA 1.448 -0.561 0 CA-C-N 123.294 2.77 . . . . 0.0 110.986 -165.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.494 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 89.2 Cg_endo -81.51 -3.83 12.1 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 CA-C-O 116.066 -1.723 . . . . 0.0 114.609 165.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.3 mpp? -81.85 125.01 30.2 Favored 'General case' 0 N--CA 1.449 -0.484 0 CA-C-N 122.312 2.324 . . . . 0.0 114.139 178.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . 0.308 0.2 OUTLIER -70.83 126.08 30.4 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.538 0 O-C-N 116.583 -3.823 . . . . 0.0 109.96 -174.796 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 154.78 -149.13 20.34 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 127.692 2.568 . . . . 0.0 116.701 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 9.6 mp -89.47 137.26 32.48 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 120.341 2.07 . . . . 0.0 115.489 -167.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . 0.251 4.2 m-20 -86.81 165.85 15.68 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 128.272 2.629 . . . . 0.0 112.762 173.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -73.02 -22.48 60.65 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-O 115.183 -2.341 . . . . 0.0 114.342 162.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 t -142.54 -54.3 0.2 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.496 0 CA-C-N 120.972 1.715 . . . . 0.0 109.443 -177.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 m -163.05 143.25 9.17 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-O 119.074 -0.489 . . . . 0.0 111.75 -164.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 133.85 -166.78 23.87 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 127.052 2.263 . . . . 0.0 117.071 -171.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 58.2 mm-40 -119.77 -4.17 10.23 Favored 'General case' 0 N--CA 1.449 -0.489 0 O-C-N 127.203 2.355 . . . . 0.0 115.855 178.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -128.93 176.83 7.55 Favored 'General case' 0 N--CA 1.449 -0.523 0 C-N-CA 129.845 3.258 . . . . 0.0 113.436 -168.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 12.5 m95 -69.62 159.64 33.05 Favored 'General case' 0 N--CA 1.449 -0.49 0 CA-C-O 125.255 2.455 . . . . 0.0 106.593 175.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.9 t70 -93.43 161.44 14.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 O-C-N 120.289 -1.507 . . . . 0.0 113.169 -176.506 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.489 ' H ' ' HD2' ' A' ' 2' ' ' PRO . 2.0 pt20 -140.49 110.83 6.67 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 172.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -80.28 176.63 9.6 Favored 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 127.016 2.126 . . . . 0.0 111.724 170.089 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -141.74 153.66 65.02 Favored Pre-proline 0 N--CA 1.449 -0.49 0 C-N-CA 129.584 3.154 . . . . 0.0 110.735 174.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -77.37 161.15 31.96 Favored 'Trans proline' 0 N--CA 1.449 -1.096 0 C-N-CA 124.576 3.518 . . . . 0.0 113.303 169.309 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 72.9 mt -81.16 24.33 0.53 Allowed 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 113.08 -1.873 . . . . 0.0 113.395 -159.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -66.07 -8.67 24.84 Favored 'General case' 0 N--CA 1.449 -0.485 0 CA-C-N 124.578 3.354 . . . . 0.0 119.246 -157.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 . . . . . 0 C--O 1.249 1.079 0 CA-C-N 122.035 2.198 . . . . 0.0 115.178 -177.241 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.516 0 N-CA-C 115.347 0.899 . . . . 0.0 115.347 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.1 Cg_endo -87.39 62.05 3.87 Favored 'Trans proline' 0 N--CA 1.45 -1.057 0 C-N-CA 123.736 2.957 . . . . 0.0 110.643 -175.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.493 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -127.72 174.77 3.98 Favored Pre-proline 0 N--CA 1.449 -0.511 0 O-C-N 120.567 -1.333 . . . . 0.0 112.055 171.201 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.493 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 65.0 Cg_endo -95.33 -14.26 0.62 Allowed 'Trans proline' 0 N--CA 1.449 -1.127 0 C-N-CA 124.261 3.307 . . . . 0.0 114.567 175.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 4.8 mpp? -65.83 111.12 3.11 Favored 'General case' 0 N--CA 1.449 -0.486 0 CA-C-N 119.701 1.137 . . . . 0.0 110.653 174.975 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -76.78 144.93 11.05 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 CA-C-N 121.694 2.043 . . . . 0.0 110.058 -174.037 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 151.49 -172.89 30.95 Favored Glycine 0 C--N 1.336 0.53 0 C-N-CA 127.255 2.36 . . . . 0.0 114.149 -163.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 73.6 mt -67.1 160.19 27.24 Favored 'General case' 0 N--CA 1.449 -0.483 0 CA-C-O 117.169 -1.396 . . . . 0.0 112.653 166.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 6.4 t0 -123.45 129.8 51.78 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 128.725 2.81 . . . . 0.0 113.047 175.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.3 t -63.78 -17.83 63.47 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 126.7 2.0 . . . . 0.0 116.291 176.219 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.4 t -119.84 -62.07 2.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.533 0 C-N-CA 125.927 1.691 . . . . 0.0 110.872 -172.021 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -167.93 161.63 13.01 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 124.472 2.082 . . . . 0.0 113.499 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 61.25 -139.23 47.5 Favored Glycine 0 CA--C 1.523 0.548 0 O-C-N 118.035 -2.916 . . . . 0.0 112.471 -176.326 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -120.81 177.22 5.17 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 127.93 2.492 . . . . 0.0 111.106 -178.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 43.6 m-85 71.94 159.39 0.21 Allowed 'General case' 0 N--CA 1.45 -0.475 0 C-N-CA 126.184 1.793 . . . . 0.0 110.445 -175.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m0 -55.92 156.56 5.12 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 115.03 1.493 . . . . 0.0 115.03 172.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 -94.7 176.76 6.15 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 116.459 2.022 . . . . 0.0 116.459 160.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -137.51 28.11 2.75 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 124.256 1.979 . . . . 0.0 111.634 165.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 8.6 m80 -75.68 163.01 27.74 Favored 'General case' 0 N--CA 1.45 -0.474 0 N-CA-C 116.869 2.174 . . . . 0.0 116.869 -168.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -137.3 159.71 68.5 Favored Pre-proline 0 N--CA 1.45 -0.474 0 O-C-N 126.163 2.165 . . . . 0.0 109.774 175.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -80.31 152.39 20.79 Favored 'Trans proline' 0 N--CA 1.449 -1.135 0 C-N-CA 124.177 3.252 . . . . 0.0 113.719 -168.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 43.4 mt -92.68 106.61 18.56 Favored 'General case' 0 N--CA 1.449 -0.525 0 CA-C-N 121.365 1.893 . . . . 0.0 114.14 -177.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.84 -11.49 2.65 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 128.514 2.725 . . . . 0.0 117.332 -177.59 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 . . . . . 0 C--O 1.25 1.089 0 C-N-CA 129.142 2.977 . . . . 0.0 113.993 -175.099 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.55 0 N-CA-C 115.01 0.764 . . . . 0.0 115.01 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 48.9 Cg_endo -95.43 16.74 0.87 Allowed 'Trans proline' 0 N--CA 1.448 -1.178 1 C-N-CA 126.198 4.598 . . . . 0.0 115.847 -167.882 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 66.9 p -67.72 171.7 4.96 Favored Pre-proline 0 N--CA 1.448 -0.535 0 O-C-N 118.372 -2.705 . . . . 0.0 112.668 178.994 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 95.5 Cg_endo -86.67 5.5 5.82 Favored 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.831 2.354 . . . . 0.0 113.166 166.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.87 108.0 20.61 Favored 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 126.298 1.839 . . . . 0.0 110.119 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.9 t -61.05 140.27 19.08 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 O-C-N 119.653 -1.904 . . . . 0.0 109.885 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 153.81 -167.72 32.18 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 117.587 1.795 . . . . 0.0 117.587 179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.9 mt -65.66 151.73 45.86 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-N 119.522 1.661 . . . . 0.0 111.816 -178.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -132.29 137.93 47.65 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 123.844 0.858 . . . . 0.0 111.754 179.272 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 9.3 m -68.16 -6.5 23.62 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 116.065 1.876 . . . . 0.0 116.065 172.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.0 t -141.65 -58.37 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 CA-C-N 120.416 1.462 . . . . 0.0 113.176 179.293 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 84.5 p -155.22 165.32 37.05 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 116.837 2.162 . . . . 0.0 116.837 -166.311 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 85.46 -147.23 22.11 Favored Glycine 0 N--CA 1.448 -0.525 0 O-C-N 120.312 -1.493 . . . . 0.0 111.935 174.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 18.3 pt20 -145.14 14.53 1.48 Allowed 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 122.434 1.111 . . . . 0.0 111.145 -177.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -117.05 170.88 8.3 Favored 'General case' 0 N--CA 1.45 -0.458 0 O-C-N 120.092 -1.63 . . . . 0.0 109.642 177.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 11.5 m95 -60.56 159.76 10.07 Favored 'General case' 0 N--CA 1.45 -0.469 0 C-N-CA 125.534 1.534 . . . . 0.0 112.703 170.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 2.6 p30 -103.83 159.4 15.67 Favored 'General case' 0 N--CA 1.449 -0.499 0 C-N-CA 125.058 1.343 . . . . 0.0 111.845 173.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 15.7 pt20 -135.76 73.05 1.45 Allowed 'General case' 0 N--CA 1.449 -0.488 0 CA-C-O 124.676 2.179 . . . . 0.0 112.099 -171.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 31.7 m170 -79.19 19.8 0.55 Allowed 'General case' 0 N--CA 1.449 -0.5 0 C-N-CA 128.482 2.713 . . . . 0.0 114.179 -169.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -144.52 158.69 53.49 Favored Pre-proline 0 N--CA 1.448 -0.525 0 C-N-CA 128.081 2.552 . . . . 0.0 110.345 -177.508 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.88 164.66 34.97 Favored 'Trans proline' 0 N--CA 1.449 -1.108 0 C-N-CA 124.274 3.316 . . . . 0.0 112.374 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -140.73 168.71 19.14 Favored 'General case' 0 N--CA 1.449 -0.476 0 C-N-CA 125.345 1.458 . . . . 0.0 111.7 -179.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -147.7 91.99 2.02 Favored 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 124.268 1.027 . . . . 0.0 111.053 168.471 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.25 1.128 0 C-N-CA 126.782 2.033 . . . . 0.0 112.735 161.535 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.534 0 N-CA-C 114.025 0.37 . . . . 0.0 114.025 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -86.8 -3.29 8.21 Favored 'Trans proline' 0 N--CA 1.449 -1.105 0 C-N-CA 122.223 1.948 . . . . 0.0 116.838 -169.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.437 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 2.6 p -81.23 170.96 13.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 CA-C-N 122.885 2.584 . . . . 0.0 111.318 -171.247 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.437 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 59.4 Cg_endo -89.33 -9.46 4.26 Favored 'Trans proline' 0 N--CA 1.449 -1.12 0 N-CA-C 116.903 1.847 . . . . 0.0 116.903 -175.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 10.5 mmt -71.03 116.26 11.12 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 119.768 1.167 . . . . 0.0 113.194 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.439 HG22 ' CE1' ' A' ' 15' ' ' TYR . 6.8 t -67.36 120.69 15.11 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.487 0 C-N-CA 125.071 1.348 . . . . 0.0 113.584 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 179.09 -111.47 0.32 Allowed Glycine 0 CA--C 1.522 0.497 0 O-C-N 120.911 -1.118 . . . . 0.0 113.293 -171.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.3 pt? -145.07 157.65 44.05 Favored 'General case' 0 N--CA 1.448 -0.547 0 N-CA-C 113.964 1.098 . . . . 0.0 113.964 176.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -124.98 135.81 53.14 Favored 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 125.435 1.494 . . . . 0.0 109.963 -177.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 11.5 m -67.78 -12.12 59.9 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 115.172 1.545 . . . . 0.0 115.172 172.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 25.4 t -140.23 -52.77 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 CA-C-N 120.162 1.346 . . . . 0.0 112.079 -167.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 85.2 p -150.16 176.2 11.05 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 120.456 1.48 . . . . 0.0 114.911 -159.826 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 44.2 -138.8 4.46 Favored Glycine 0 C--N 1.335 0.512 0 O-C-N 120.601 -1.312 . . . . 0.0 115.96 -170.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 11.5 pt20 -135.51 -25.52 1.3 Allowed 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 124.653 1.181 . . . . 0.0 113.22 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . 0.439 ' CE1' HG22 ' A' ' 6' ' ' VAL . 17.4 m-30 -89.81 175.73 7.11 Favored 'General case' 0 N--CA 1.45 -0.453 0 C-N-CA 126.002 1.721 . . . . 0.0 111.214 -179.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 3.1 m95 -51.07 138.12 20.39 Favored 'General case' 0 N--CA 1.449 -0.501 0 C-N-CA 127.344 2.257 . . . . 0.0 114.306 -178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.446 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.7 p-10 -79.27 154.08 29.42 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 121.716 -0.615 . . . . 0.0 112.54 156.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -82.53 -35.05 27.62 Favored 'General case' 0 N--CA 1.449 -0.512 0 CA-C-O 123.395 1.569 . . . . 0.0 113.207 168.18 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 12.5 m-70 -68.63 130.17 42.06 Favored 'General case' 0 N--CA 1.448 -0.556 0 C-N-CA 129.25 3.02 . . . . 0.0 113.494 -155.553 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -54.21 122.36 36.16 Favored Pre-proline 0 N--CA 1.449 -0.506 0 C-N-CA 125.506 1.523 . . . . 0.0 114.421 -178.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -75.85 92.89 1.02 Allowed 'Trans proline' 0 N--CA 1.45 -1.081 0 C-N-CA 123.881 3.054 . . . . 0.0 111.47 -173.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.462 HD23 ' H ' ' A' ' 22' ' ' LEU . 2.5 pt? -61.48 148.91 40.37 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 124.933 1.293 . . . . 0.0 113.787 175.477 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -132.67 25.95 4.37 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 125.904 1.681 . . . . 0.0 114.113 -173.325 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 38.5 t70 . . . . . 0 C--O 1.25 1.098 0 C-N-CA 127.115 2.166 . . . . 0.0 113.904 -174.879 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.522 0.518 0 N-CA-C 116.128 1.211 . . . . 0.0 116.128 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.7 Cg_endo -94.14 12.4 1.67 Allowed 'Trans proline' 0 N--CA 1.449 -1.124 0 C-N-CA 124.64 3.56 . . . . 0.0 116.938 -167.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 28.1 p -71.39 174.72 3.5 Favored Pre-proline 0 N--CA 1.449 -0.481 0 N-CA-C 113.327 0.862 . . . . 0.0 113.327 175.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 88.2 Cg_endo -91.64 -1.56 4.47 Favored 'Trans proline' 0 N--CA 1.448 -1.162 0 C-N-CA 123.238 2.625 . . . . 0.0 113.446 169.75 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 70.1 mtm -78.67 115.25 18.25 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.787 -2.446 . . . . 0.0 108.314 -176.426 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 4.0 t -70.23 127.25 31.89 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.497 0 O-C-N 119.015 -2.303 . . . . 0.0 112.008 -175.363 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 168.02 -165.39 38.71 Favored Glycine 0 C--N 1.335 0.49 0 C-N-CA 125.905 1.717 . . . . 0.0 112.247 -178.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 60.0 mt -82.59 166.84 18.88 Favored 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 125.268 1.427 . . . . 0.0 113.778 179.311 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.8 t70 -140.09 133.38 29.81 Favored 'General case' 0 N--CA 1.449 -0.496 0 C-N-CA 125.831 1.652 . . . . 0.0 111.203 -175.67 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m -62.08 -11.99 16.92 Favored 'General case' 0 N--CA 1.45 -0.462 0 N-CA-C 116.324 1.972 . . . . 0.0 116.324 173.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.7 t -130.62 -66.7 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 C-N-CA 124.989 1.316 . . . . 0.0 110.716 -176.404 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 14.1 p -162.59 168.65 21.45 Favored 'General case' 0 N--CA 1.449 -0.514 0 CA-C-N 120.316 1.416 . . . . 0.0 112.841 -160.536 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 77.64 -162.4 50.62 Favored Glycine 0 N--CA 1.448 -0.543 0 O-C-N 120.476 -1.39 . . . . 0.0 113.614 -179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.0 pt20 -131.11 7.87 4.68 Favored 'General case' 0 N--CA 1.448 -0.542 0 C-N-CA 125.485 1.514 . . . . 0.0 114.493 -169.859 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -121.49 174.35 6.83 Favored 'General case' 0 N--CA 1.449 -0.498 0 C-N-CA 126.695 1.998 . . . . 0.0 110.304 172.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 5.8 m95 -59.05 161.61 4.97 Favored 'General case' 0 N--CA 1.449 -0.505 0 C-N-CA 127.655 2.382 . . . . 0.0 114.912 176.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.419 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 25.8 t0 -105.85 146.07 30.39 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 126.593 1.957 . . . . 0.0 110.539 170.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -77.14 -11.59 59.83 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 114.966 1.469 . . . . 0.0 114.966 -175.667 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 21.4 t-80 -68.78 171.63 7.57 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.815 1.646 . . . . 0.0 112.019 177.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -111.3 83.33 3.97 Favored Pre-proline 0 N--CA 1.449 -0.524 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 166.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -62.05 130.15 29.78 Favored 'Trans proline' 0 N--CA 1.448 -1.177 0 C-N-CA 123.573 2.849 . . . . 0.0 110.94 -168.115 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . 0.283 38.1 mt 61.23 -75.66 0.03 OUTLIER 'General case' 0 N--CA 1.45 -0.461 0 C-N-CA 127.885 2.474 . . . . 0.0 111.878 -161.048 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -166.25 164.05 17.72 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 126.819 2.048 . . . . 0.0 111.893 164.35 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 32.1 m-20 . . . . . 0 C--O 1.249 1.075 0 C-N-CA 128.583 2.753 . . . . 0.0 112.662 167.525 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.568 0 CA-C-O 118.305 -1.275 . . . . 0.0 115.804 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.3 Cg_endo -80.85 7.94 4.59 Favored 'Trans proline' 0 N--CA 1.45 -1.045 1 C-N-CA 126.35 4.7 . . . . 0.0 118.578 -173.29 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.508 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 41.6 p -69.1 168.6 14.85 Favored Pre-proline 0 N--CA 1.45 -0.449 0 C-N-CA 125.419 1.487 . . . . 0.0 114.268 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.508 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 12.8 Cg_endo -84.21 -2.5 10.08 Favored 'Trans proline' 0 N--CA 1.448 -1.154 1 C-N-CA 125.962 4.441 . . . . 0.0 118.659 164.206 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 46.4 mtt -84.69 111.75 19.86 Favored 'General case' 0 N--CA 1.448 -0.538 0 O-C-N 119.801 -1.812 . . . . 0.0 108.785 179.728 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 3.1 t -57.08 140.83 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 CA-C-N 120.001 1.273 . . . . 0.0 112.08 173.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 146.42 -164.98 28.35 Favored Glycine 0 CA--C 1.522 0.517 0 CA-C-O 124.751 2.306 . . . . 0.0 114.838 179.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 94.6 mt -74.25 125.78 29.17 Favored 'General case' 0 N--CA 1.449 -0.518 0 C-N-CA 126.637 1.975 . . . . 0.0 112.803 176.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.3 t70 -97.36 162.07 13.5 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 127.869 2.467 . . . . 0.0 108.297 177.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.0 m -76.55 -16.09 59.7 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.378 -2.702 . . . . 0.0 114.324 168.028 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.9 t -132.53 -65.45 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.494 0 C-N-CA 126.951 2.1 . . . . 0.0 111.532 -175.148 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.0 p -156.85 165.01 37.4 Favored 'General case' 0 N--CA 1.45 -0.455 0 CA-C-N 119.0 0.818 . . . . 0.0 109.873 -157.455 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 82.5 -161.47 40.78 Favored Glycine 0 C--N 1.335 0.493 0 C-N-CA 125.904 1.716 . . . . 0.0 112.337 176.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.32 6.8 pt20 -126.69 28.4 5.89 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 117.702 -3.234 . . . . 0.0 114.686 178.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 25.4 m-85 -135.21 165.65 24.93 Favored 'General case' 0 N--CA 1.448 -0.537 0 C-N-CA 128.534 2.734 . . . . 0.0 111.919 -178.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 20.2 m95 -65.44 162.82 17.04 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 126.23 1.812 . . . . 0.0 114.226 -179.482 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 18.0 t0 -102.25 160.55 14.43 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.888 2.181 . . . . 0.0 116.888 165.125 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -81.99 -12.37 58.36 Favored 'General case' 0 N--CA 1.45 -0.468 0 C-N-CA 125.483 1.513 . . . . 0.0 114.596 -178.299 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 6.4 t60 -69.73 168.35 15.16 Favored 'General case' 0 N--CA 1.45 -0.453 0 O-C-N 121.305 -0.872 . . . . 0.0 112.211 171.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -128.02 93.24 39.83 Favored Pre-proline 0 N--CA 1.45 -0.472 0 N-CA-C 106.178 -1.786 . . . . 0.0 106.178 173.529 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 11.5 Cg_endo -70.39 142.77 45.99 Favored 'Trans proline' 0 N--CA 1.448 -1.153 0 C-N-CA 122.47 2.113 . . . . 0.0 110.971 172.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -107.59 176.4 5.16 Favored 'General case' 0 N--CA 1.449 -0.492 0 N-CA-C 116.194 1.924 . . . . 0.0 116.194 -177.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . 50.28 35.71 11.2 Favored 'General case' 0 N--CA 1.448 -0.553 0 C-N-CA 129.163 2.985 . . . . 0.0 113.074 173.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 . . . . . 0 C--O 1.249 1.037 0 CA-C-N 120.445 1.475 . . . . 0.0 113.163 167.536 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.414 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 116.572 1.389 . . . . 0.0 116.572 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -78.69 14.87 1.56 Allowed 'Trans proline' 0 N--CA 1.449 -1.138 1 C-N-CA 127.117 5.212 . . . . 0.0 117.49 -172.094 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.568 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 51.9 p -84.88 173.01 7.74 Favored Pre-proline 0 N--CA 1.45 -0.462 0 O-C-N 116.488 -3.882 . . . . 0.0 112.302 -177.305 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.568 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 11.1 Cg_endo -86.37 -7.11 7.94 Favored 'Trans proline' 0 N--CA 1.45 -1.087 1 C-N-CA 126.785 4.99 . . . . 0.0 117.783 162.551 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 66.2 mtm -81.0 103.69 11.0 Favored 'General case' 0 N--CA 1.449 -0.486 0 C-N-CA 126.362 1.865 . . . . 0.0 112.26 179.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 30.3 m -60.11 155.64 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 O-C-N 118.745 -2.472 . . . . 0.0 113.281 -179.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 125.69 -176.78 17.26 Favored Glycine 0 CA--C 1.522 0.504 0 O-C-N 121.117 -0.989 . . . . 0.0 113.695 -167.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.9 pt? -66.33 148.5 51.77 Favored 'General case' 0 N--CA 1.449 -0.502 0 C-N-CA 127.634 2.374 . . . . 0.0 117.241 -175.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -121.66 130.2 53.3 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 114.662 -1.153 . . . . 0.0 112.841 179.576 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 40.8 m -64.37 -16.84 63.03 Favored 'General case' 0 N--CA 1.449 -0.486 0 N-CA-C 113.83 1.048 . . . . 0.0 113.83 176.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 18.6 t -111.52 -75.23 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.52 0 O-C-N 119.939 -1.726 . . . . 0.0 108.997 -170.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 34.1 m -160.59 169.29 23.22 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 129.488 3.115 . . . . 0.0 114.254 -167.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 70.89 -140.75 31.93 Favored Glycine 0 C--N 1.336 0.572 0 CA-C-N 121.052 1.751 . . . . 0.0 113.664 169.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.41 -177.29 3.93 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.082 2.953 . . . . 0.0 112.688 173.878 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 14.4 m-85 59.98 167.91 0.07 Allowed 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 128.204 2.601 . . . . 0.0 115.641 -165.416 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 6.2 m95 -63.4 160.36 16.32 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 129.783 3.233 . . . . 0.0 112.19 171.34 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.414 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 2.5 p30 -104.41 166.02 10.67 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.783 1.633 . . . . 0.0 113.933 177.478 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 9.1 tt0 -161.35 156.71 24.24 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 127.182 2.193 . . . . 0.0 109.083 -160.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 19.4 t-80 -65.02 172.52 2.88 Favored 'General case' 0 N--CA 1.449 -0.493 0 CA-C-O 122.759 1.266 . . . . 0.0 108.876 156.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -47.54 143.66 5.43 Favored Pre-proline 0 N--CA 1.449 -0.498 0 N-CA-C 117.134 2.272 . . . . 0.0 117.134 -166.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -68.0 131.88 24.96 Favored 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 124.917 3.745 . . . . 0.0 114.593 -171.109 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 27.0 mt -72.79 68.37 0.86 Allowed 'General case' 0 N--CA 1.449 -0.482 0 C-N-CA 129.479 3.112 . . . . 0.0 107.242 171.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -74.94 -11.7 60.18 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 114.682 1.364 . . . . 0.0 114.682 -154.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 C--O 1.25 1.093 0 C-N-CA 127.922 2.489 . . . . 0.0 109.305 174.91 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.535 0 N-CA-C 116.451 1.34 . . . . 0.0 116.451 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_endo -86.11 -0.07 8.34 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 124.507 3.471 . . . . 0.0 115.595 -177.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 5.7 p -87.23 162.23 43.88 Favored Pre-proline 0 N--CA 1.449 -0.48 0 CA-C-N 118.054 0.388 . . . . 0.0 111.791 -173.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_endo -91.83 11.93 2.28 Favored 'Trans proline' 0 N--CA 1.45 -1.085 0 C-N-CA 124.557 3.505 . . . . 0.0 112.359 -179.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 87.3 mmm -83.7 115.72 22.32 Favored 'General case' 0 N--CA 1.45 -0.474 0 O-C-N 120.822 -1.174 . . . . 0.0 111.474 171.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.9 p -75.69 120.82 26.24 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.479 0 CA-C-N 121.122 1.783 . . . . 0.0 111.234 -176.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.31 -171.64 44.71 Favored Glycine 0 C--N 1.335 0.488 0 C-N-CA 124.63 1.11 . . . . 0.0 111.274 -171.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -71.25 147.31 48.32 Favored 'General case' 0 N--CA 1.448 -0.536 0 O-C-N 121.028 -1.277 . . . . 0.0 112.126 177.024 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 4.5 t0 -101.06 103.25 14.34 Favored 'General case' 0 N--CA 1.45 -0.446 0 O-C-N 120.9 -1.125 . . . . 0.0 111.288 176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 14.4 m -61.92 -14.21 32.23 Favored 'General case' 0 N--CA 1.448 -0.545 0 CA-C-O 117.634 -1.174 . . . . 0.0 113.95 178.237 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 -75.85 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.502 0 CA-C-N 120.208 1.367 . . . . 0.0 109.899 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 7.6 t -169.64 171.69 7.34 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.739 2.016 . . . . 0.0 112.366 179.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.96 -153.15 52.81 Favored Glycine 0 C--N 1.336 0.542 0 O-C-N 119.708 -1.87 . . . . 0.0 111.11 -169.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 7.0 pt20 -115.63 -177.75 3.23 Favored 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.325 1.45 . . . . 0.0 111.559 176.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 60.5 176.52 0.1 Allowed 'General case' 0 N--CA 1.449 -0.488 0 O-C-N 120.831 -1.168 . . . . 0.0 114.022 -174.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 8.4 m95 -65.82 146.28 54.94 Favored 'General case' 0 N--CA 1.45 -0.445 0 O-C-N 117.804 -3.06 . . . . 0.0 115.196 178.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.483 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 5.2 p-10 -64.13 166.32 7.94 Favored 'General case' 0 N--CA 1.449 -0.483 0 C-N-CA 125.625 1.57 . . . . 0.0 114.312 157.173 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 8.8 pt20 -117.1 79.58 1.36 Allowed 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 128.178 2.591 . . . . 0.0 110.604 162.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 3.6 m-70 64.05 164.25 0.13 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 131.634 3.974 . . . . 0.0 111.781 -159.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -117.56 73.76 8.34 Favored Pre-proline 0 N--CA 1.448 -0.547 0 N-CA-C 105.402 -2.073 . . . . 0.0 105.402 160.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -76.78 171.75 17.44 Favored 'Trans proline' 0 N--CA 1.449 -1.133 0 C-N-CA 123.536 2.824 . . . . 0.0 115.656 -161.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . 0.528 HD23 ' H ' ' A' ' 22' ' ' LEU . 1.8 pt? -103.66 176.29 5.2 Favored 'General case' 0 N--CA 1.449 -0.509 0 C-N-CA 127.554 2.342 . . . . 0.0 111.116 166.725 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -142.32 -23.49 0.67 Allowed 'General case' 0 N--CA 1.449 -0.497 0 CA-C-O 118.085 -0.959 . . . . 0.0 110.55 166.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 4.2 p30 . . . . . 0 C--O 1.251 1.135 0 C-N-CA 128.491 2.716 . . . . 0.0 112.428 -178.186 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.479 ' HA3' ' HA ' ' A' ' 17' ' ' ASP . . . . . . . . 0 CA--C 1.523 0.532 0 N-CA-C 121.099 3.2 . . . . 0.0 121.099 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -88.55 -4.85 6.42 Favored 'Trans proline' 0 N--CA 1.449 -1.104 0 N-CA-C 121.488 3.611 . . . . 0.0 121.488 -175.287 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.464 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 10.4 p -65.43 155.52 84.94 Favored Pre-proline 0 N--CA 1.449 -0.492 0 C-N-CA 123.701 0.8 . . . . 0.0 112.3 -174.454 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.464 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 96.1 Cg_endo -79.62 18.23 1.14 Allowed 'Trans proline' 0 N--CA 1.45 -1.078 0 N-CA-C 117.46 2.061 . . . . 0.0 117.46 -165.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 20.6 mtm -102.5 116.21 32.14 Favored 'General case' 0 N--CA 1.449 -0.489 0 N-CA-C 107.254 -1.387 . . . . 0.0 107.254 170.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.4 p -66.68 130.99 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.508 0 O-C-N 117.263 -3.398 . . . . 0.0 110.463 177.374 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.22 -147.14 9.07 Favored Glycine 0 C--N 1.336 0.535 0 C-N-CA 124.909 1.242 . . . . 0.0 115.612 -172.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 23.5 mt -97.78 149.56 22.2 Favored 'General case' 0 N--CA 1.449 -0.49 0 C-N-CA 125.396 1.479 . . . . 0.0 113.308 -177.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -121.81 151.59 40.44 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 128.097 2.559 . . . . 0.0 109.249 174.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 66.3 m -72.19 -36.28 69.19 Favored 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 126.102 1.761 . . . . 0.0 109.945 -176.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.1 t -129.73 -47.65 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -176.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -157.78 149.31 21.68 Favored 'General case' 0 N--CA 1.449 -0.501 0 CA-C-O 121.423 0.63 . . . . 0.0 112.512 -170.158 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 118.38 179.52 17.06 Favored Glycine 0 C--N 1.336 0.577 0 C-N-CA 127.635 2.54 . . . . 0.0 115.809 -168.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 51.3 mt-30 -121.56 -0.35 9.76 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 125.802 1.641 . . . . 0.0 114.408 174.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 5.6 m-85 -123.42 -168.21 1.74 Allowed 'General case' 0 N--CA 1.45 -0.47 0 C-N-CA 128.996 2.918 . . . . 0.0 111.441 -175.678 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 2.7 m95 -71.03 137.71 49.25 Favored 'General case' 0 N--CA 1.449 -0.523 0 CA-C-O 126.751 3.167 . . . . 0.0 113.166 175.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . 0.479 ' HA ' ' HA3' ' A' ' 1' ' ' GLY . 0.2 OUTLIER -72.68 134.22 44.97 Favored 'General case' 0 N--CA 1.45 -0.464 0 O-C-N 118.893 -2.379 . . . . 0.0 112.551 159.665 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . 0.327 59.8 mt-30 59.91 14.04 4.01 Favored 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 119.719 3.229 . . . . 0.0 119.719 158.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 61.7 t60 -55.01 -64.52 0.81 Allowed 'General case' 0 N--CA 1.448 -0.538 0 C-N-CA 124.531 1.132 . . . . 0.0 113.094 167.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -170.82 149.48 2.85 Favored Pre-proline 0 N--CA 1.448 -0.525 0 CA-C-N 112.073 -2.33 . . . . 0.0 113.469 168.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -85.3 105.59 0.91 Allowed 'Trans proline' 0 N--CA 1.448 -1.158 1 C-N-CA 127.445 5.43 . . . . 0.0 110.575 160.101 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 91.5 mt -110.97 -179.55 3.77 Favored 'General case' 0 N--CA 1.45 -0.473 0 O-C-N 124.388 1.055 . . . . 0.0 112.593 -171.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -143.27 -9.02 0.76 Allowed 'General case' 0 N--CA 1.448 -0.544 0 N-CA-C 115.094 1.516 . . . . 0.0 115.094 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 11.3 t70 . . . . . 0 C--O 1.25 1.109 0 C-N-CA 131.173 3.789 . . . . 0.0 113.984 162.539 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.523 0.536 0 N-CA-C 116.022 1.169 . . . . 0.0 116.022 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -88.9 3.8 5.58 Favored 'Trans proline' 0 N--CA 1.449 -1.121 1 C-N-CA 128.832 6.355 . . . . 0.0 118.196 -172.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.444 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 22.1 p -63.96 171.13 2.67 Favored Pre-proline 0 N--CA 1.448 -0.532 0 CA-C-N 119.122 0.873 . . . . 0.0 110.242 173.911 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.444 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.6 Cg_endo -94.01 9.15 2.18 Favored 'Trans proline' 0 N--CA 1.449 -1.091 1 C-N-CA 125.342 4.028 . . . . 0.0 112.793 166.24 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 40.0 mtp -92.11 111.68 23.33 Favored 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.547 2.339 . . . . 0.0 110.439 175.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.6 139.14 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 O-C-N 120.096 -1.628 . . . . 0.0 109.959 -178.18 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 148.56 -155.79 26.56 Favored Glycine 0 C--N 1.335 0.521 0 C-N-CA 128.428 2.918 . . . . 0.0 113.186 -174.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 8' ' ' LEU . 40.6 mt -85.48 136.28 33.49 Favored 'General case' 0 N--CA 1.449 -0.524 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -173.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -79.91 -177.0 5.75 Favored 'General case' 0 N--CA 1.45 -0.437 0 C-N-CA 128.843 2.857 . . . . 0.0 111.849 176.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 26.8 p -64.72 -26.14 68.24 Favored 'General case' 0 N--CA 1.45 -0.46 0 C-N-CA 125.554 1.541 . . . . 0.0 113.345 171.388 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 t -126.18 -33.96 0.9 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.47 0 N-CA-C 115.962 1.838 . . . . 0.0 115.962 -177.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 3.8 t -147.38 -166.37 2.5 Favored 'General case' 0 N--CA 1.449 -0.489 0 CA-C-O 123.853 1.787 . . . . 0.0 112.051 -170.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -65.57 -177.8 7.11 Favored Glycine 0 CA--C 1.523 0.548 1 O-C-N 115.443 -4.536 . . . . 0.0 112.633 161.059 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . 0.307 35.5 mt-30 72.77 77.89 0.15 Allowed 'General case' 0 N--CA 1.45 -0.459 0 C-N-CA 127.442 2.297 . . . . 0.0 114.908 -173.457 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 59.9 m-85 70.2 160.52 0.21 Allowed 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 125.835 1.654 . . . . 0.0 114.812 167.173 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 21.7 m95 -67.2 157.97 32.46 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 173.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . 0.297 3.2 p30 -93.21 165.24 12.91 Favored 'General case' 0 N--CA 1.449 -0.479 0 C-N-CA 127.229 2.212 . . . . 0.0 114.889 176.011 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.493 ' C ' ' H ' ' A' ' 20' ' ' ALA . 5.9 tt0 -135.5 6.32 3.24 Favored 'General case' 0 N--CA 1.448 -0.529 0 C-N-CA 127.231 2.212 . . . . 0.0 114.202 -169.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 56.53 -14.99 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.473 0 C-N-CA 128.08 2.552 . . . . 0.0 114.764 -163.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.493 ' H ' ' C ' ' A' ' 18' ' ' GLN . . . -63.89 142.16 98.08 Favored Pre-proline 0 N--CA 1.449 -0.488 0 O-C-N 119.895 -1.753 . . . . 0.0 112.024 176.062 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_endo -70.6 172.13 14.06 Favored 'Trans proline' 0 N--CA 1.449 -1.122 0 C-N-CA 123.699 2.933 . . . . 0.0 113.055 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 90.4 mt -69.05 176.67 3.05 Favored 'General case' 0 N--CA 1.449 -0.478 0 O-C-N 118.887 -2.383 . . . . 0.0 114.541 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . 0.446 . . 75.1 38.2 0.44 Allowed 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 115.807 1.781 . . . . 0.0 115.807 -169.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 3.5 p-10 . . . . . 0 C--O 1.25 1.104 0 N-CA-C 118.121 2.638 . . . . 0.0 118.121 177.904 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.511 0 N-CA-C 114.301 0.48 . . . . 0.0 114.301 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 42.3 Cg_endo -88.32 8.33 4.11 Favored 'Trans proline' 0 N--CA 1.449 -1.142 0 C-N-CA 124.915 3.743 . . . . 0.0 115.111 -169.264 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.537 HG23 ' H ' ' A' ' 18' ' ' GLN . 68.4 p -63.64 168.31 5.76 Favored Pre-proline 0 N--CA 1.449 -0.479 0 N-CA-C 114.286 1.217 . . . . 0.0 114.286 -178.988 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.485 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 10.1 Cg_endo -90.2 19.86 1.12 Allowed 'Trans proline' 0 N--CA 1.45 -1.088 0 C-N-CA 124.72 3.613 . . . . 0.0 112.764 163.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 79.4 mtm -102.57 95.42 6.22 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 127.797 2.439 . . . . 0.0 111.542 179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 9.9 p -52.0 147.43 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.498 0 CA-C-N 120.051 1.296 . . . . 0.0 113.725 174.204 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 143.04 -144.27 13.6 Favored Glycine 0 CA--C 1.522 0.481 0 C-N-CA 127.339 2.4 . . . . 0.0 111.39 -172.685 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 51.5 mt -115.74 141.22 48.38 Favored 'General case' 0 N--CA 1.449 -0.494 0 CA-C-O 122.821 1.296 . . . . 0.0 109.435 175.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -74.06 166.97 22.47 Favored 'General case' 0 N--CA 1.449 -0.505 0 CA-C-N 111.758 -2.474 . . . . 0.0 111.732 176.028 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 92.0 p -74.76 -5.82 45.48 Favored 'General case' 0 N--CA 1.449 -0.484 0 C-N-CA 123.891 0.877 . . . . 0.0 112.493 173.009 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.6 t -124.74 -63.04 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 C-N-CA 128.313 2.645 . . . . 0.0 111.716 -177.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 4.7 t -125.92 -164.5 1.32 Allowed 'General case' 0 N--CA 1.45 -0.468 0 N-CA-C 113.669 0.988 . . . . 0.0 113.669 -173.17 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . -71.6 179.12 34.3 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-O 118.32 -1.267 . . . . 0.0 114.219 163.443 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 52.8 mt-30 61.42 91.94 0.06 Allowed 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.217 2.207 . . . . 0.0 113.707 177.117 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 7.5 m-85 71.02 155.31 0.14 Allowed 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 127.506 2.322 . . . . 0.0 114.089 166.491 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 24.8 m95 -67.85 167.83 12.76 Favored 'General case' 0 N--CA 1.449 -0.489 0 C-N-CA 127.351 2.261 . . . . 0.0 114.755 -178.259 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 21.8 t70 -114.96 98.1 6.62 Favored 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 127.263 2.225 . . . . 0.0 111.689 177.037 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . 0.537 ' H ' HG23 ' A' ' 3' ' ' THR . 36.6 tt0 -152.07 132.72 13.95 Favored 'General case' 0 N--CA 1.448 -0.54 0 C-N-CA 124.706 1.202 . . . . 0.0 108.747 157.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 11.4 m170 59.12 -176.08 0.09 Allowed 'General case' 0 N--CA 1.449 -0.481 0 C-N-CA 126.917 2.087 . . . . 0.0 113.799 -168.62 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -139.72 70.07 37.29 Favored Pre-proline 0 N--CA 1.449 -0.499 0 C-N-CA 123.667 0.787 . . . . 0.0 112.399 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -60.9 116.66 3.5 Favored 'Trans proline' 0 N--CA 1.449 -1.089 0 C-N-CA 124.382 3.388 . . . . 0.0 111.218 176.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 3.0 pp -69.33 -11.06 60.49 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 125.163 1.385 . . . . 0.0 112.103 175.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -55.9 160.69 2.59 Favored 'General case' 0 N--CA 1.449 -0.481 0 CA-C-N 121.196 1.817 . . . . 0.0 114.769 168.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.0 p-10 . . . . . 0 C--O 1.25 1.124 0 C-N-CA 128.847 2.859 . . . . 0.0 113.651 -168.815 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.522 0.498 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -79.12 -13.88 13.72 Favored 'Trans proline' 0 N--CA 1.448 -1.191 0 C-N-CA 123.05 2.5 . . . . 0.0 116.68 -169.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.516 ' HB ' ' HD2' ' A' ' 4' ' ' PRO . 18.1 p -62.95 163.37 16.7 Favored Pre-proline 0 N--CA 1.449 -0.487 0 C-N-CA 127.229 2.212 . . . . 0.0 114.04 -168.874 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' PRO . . . . . 0.516 ' HD2' ' HB ' ' A' ' 3' ' ' THR . 22.4 Cg_endo -91.57 8.94 3.0 Favored 'Trans proline' 0 N--CA 1.448 -1.149 0 C-N-CA 124.727 3.618 . . . . 0.0 112.533 175.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' MET . . . . . . . . . . . . . 68.5 mtm -88.56 100.11 12.83 Favored 'General case' 0 N--CA 1.448 -0.554 0 C-N-CA 126.351 1.86 . . . . 0.0 110.043 177.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 10.5 p -70.88 132.46 33.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 CA-C-O 121.382 0.611 . . . . 0.0 111.627 -178.53 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 163.62 -102.36 0.2 Allowed Glycine 0 CA--C 1.522 0.488 0 N-CA-C 118.326 2.09 . . . . 0.0 118.326 -174.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 35.2 tp -138.68 126.09 21.76 Favored 'General case' 0 N--CA 1.451 -0.417 0 O-C-N 118.264 -2.904 . . . . 0.0 110.729 -176.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -88.55 147.08 24.79 Favored 'General case' 0 N--CA 1.449 -0.494 0 C-N-CA 129.71 3.204 . . . . 0.0 110.48 177.469 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -77.89 -3.88 43.94 Favored 'General case' 0 N--CA 1.451 -0.418 0 O-C-N 118.776 -2.453 . . . . 0.0 112.264 173.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.69 -76.56 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 C-N-CA 129.673 3.189 . . . . 0.0 108.846 -173.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' SER . . . . . . . . . . . . . 1.4 t -162.15 172.77 15.27 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 166.758 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 112.63 -164.79 12.03 Favored Glycine 0 C--N 1.335 0.497 0 C-N-CA 124.27 0.938 . . . . 0.0 113.765 -169.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -119.86 6.99 10.9 Favored 'General case' 0 N--CA 1.449 -0.521 0 C-N-CA 125.499 1.519 . . . . 0.0 113.477 165.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' TYR . . . . . . . . . . . . . 37.9 m-85 -114.39 156.82 23.77 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.344 1.458 . . . . 0.0 110.351 -178.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' TRP . . . . . . . . . . . . . 38.2 m95 -59.74 173.37 0.58 Allowed 'General case' 0 N--CA 1.449 -0.482 0 O-C-N 117.556 -3.215 . . . . 0.0 114.617 178.244 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -124.67 142.78 51.13 Favored 'General case' 0 N--CA 1.449 -0.475 0 C-N-CA 125.254 1.422 . . . . 0.0 113.495 171.888 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.09 1.69 4.26 Favored 'General case' 0 N--CA 1.449 -0.5 0 N-CA-C 116.206 1.928 . . . . 0.0 116.206 175.046 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' HIS . . . . . . . . . . . . . 66.5 m-70 71.54 -175.66 0.18 Allowed 'General case' 0 N--CA 1.449 -0.508 0 C-N-CA 127.368 2.267 . . . . 0.0 111.429 -167.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 52.07 66.16 5.42 Favored Pre-proline 0 N--CA 1.449 -0.504 0 C-N-CA 128.915 2.886 . . . . 0.0 114.487 176.608 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.28 173.32 5.31 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 O-C-N 125.134 2.123 . . . . 0.0 112.183 -178.401 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -136.28 -0.64 2.44 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 126.659 1.984 . . . . 0.0 115.737 -172.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -77.59 40.51 0.3 Allowed 'General case' 0 N--CA 1.449 -0.507 1 C-N-CA 132.597 4.359 . . . . 0.0 113.777 174.325 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 . . . . . 0 C--O 1.251 1.164 0 C-N-CA 130.66 3.584 . . . . 0.0 112.772 175.671 . . . . . . . . 0 0 . 1 stop_ save_